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RESUMO 
A remodelação óssea é regulada por um equilíbrio entre as actividades osteoblástica e 
osteoclástica. No entanto, em condições clínicas complexas, como sejam as fracturas críticas, a 
regeneração óssea fica comprometida, sendo requerido um auxílio externo. Deste modo, novos 
métodos que permitam regular a homeostasia do osso têm sido estudados. 
O Neuropéptido Y (NPY) exerce um papel importante na regulação do metabolismo e massa 
óssea. Estudos realizados no receptor Y1 (um dos 5 receptores do sistema NPY) demonstraram 
que o seu bloqueio tem um impacto positivo na massa óssea. No entanto, o receptor Y1, que se 
encontra nas membranas celulares, tem uma ampla distribuição ao longo do organismo, com 
impacto em outros sistemas fisiológicos para além do osso. Deste modo, o objectivo geral deste 
projecto consiste na concepção de um sistema de entrega local de fármacos para a entrega no 
meio extracelular do BIBP3226, um potente e selectivo antagonista do receptor Y1.  Com este 
objectivo, sistemas baseados em partículas e nanofibras foram preparados e optimizados. 
Estudos revelaram que para tamanhos abaixo de 200 nm e acima de 500 nm, as partículas 
têm tendência a ser internalizadas por, respectivamente, células não-fagocíticas e fagocíticas, 
limitando assim a pretendida distribuição extracelular do fármaco. Deste modo, através da 
aplicação dos métodos de Salting-out e Nanoprecipitação, foram preparadas partículas de 
Poli(ácido lático-co-ácido glicólico) com tamanhos compreendidos entre 100 e 1000 nm, de 
modo a testar a hipótese formulada sobre a internalização em células osteoclásticas derivadas 
da medula óssea. Resultados mostraram que se uma célula estiver capacitada de realizar 
fagocitose, ela irá internalizar partículas com tamanhos acima de 500 nm numa escala superior 
quando comparado a partículas de tamanhos inferiores a 500 nm. Em adição, foi ainda notável 
que células com mais de 8 núcleos, internalizam menos que células com 2 ou 3 núcleos, 
levando a concluir que à medida que a célula é mais matura em relação ao fenótipo 
osteoclástico, menor é a sua capacidade de internalizar partículas. Num estudo realizado em 
paralelo, os volumes utilizados no método de Salting-out foram variados. Os resultados desta 
variação mostraram diferenças significativas na eficiência de encapsulação das partículas, mas 
não para nos seus tamanhos.  
Relativamente às nanofibras, estas foram preparadas por Electrospinning, usando 
Policaprolactona. Estes sistemas têm não só a capacidade de realizar uma entrega de fármacos 
eficiente, como também fornecem suporte como scaffold. Diferentes formulações, no que diz 
respeito à concentração de polímero e tipo de solvente orgânico, foram testadas. No entanto, 
devido à degradação do polímero, o procedimento não foi optimizado. Deste modo, novas 
experiências neste tópico devem ser realizadas. 
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ABSTRACT 
Bone remodeling is tight regulated by an equilibrium between the osteoblastic and 
osteoclastic activity. However, in complex clinical conditions, such as critical fractures, bone 
regeneration is impaired and external help is required. Therefore, new methods of controlling 
bone homeostasis have been studied. 
Neuropeptide Y (NPY) was found to have an important role in the regulation of bone 
metabolism and mass. In effect, studies have shown that blocking Y1 receptor (one of the 5 
receptors from the NPY system) has a positive impact in bone mass. However, Y1 receptor, 
which is located at cell membranes, has a wide distribution throughout the body, with impact 
in other physiological systems. Therefore, the overall goal of the project is the design of a local 
drug delivery system for the extracellular delivery of BIBP3226, a potent and selective Y1 
antagonist. Therefore, particles and nanofibers based systems were optimized and prepared.  
Studies have revealed that for sizes below 200 nm and above 500 nm, particles have a 
tendency to be internalized by non-phagocytic and phagocytic cells, respectively, thereby 
hampering the aimed extracellular delivery. Therefore, the Salting-out and Nanoprecipitation 
methods were applied in the preparation of Poly(lactide-co-glycolide) particles with sizes 
ranging from 100 nm to 1000 nm, in order to test the abovementioned internalization 
hypothesis in Bone Marrow derived Osteoclast Lineage cells. Results have shown that if a cell is 
capable of internalize particles with sizes above 500 nm (i.e., if a cell is capable of performing 
phagocytosis), it will internalize them in a larger scale than particles with sizes below 500 nm, 
as Large particles were, in a general way, more internalized than the other differently sized 
particles. Furthermore it was noticeable a tendency for a lower internalization in cells with 
more than 8 nuclei, leading to the conclusion that as the cell is more mature towards 
osteoclasts phenotype, it has less capacity to internalize particles. In a parallel study, the 
volumes used in the preparation of particles by Salting-out were varied in order to assess if this 
variability had influence on the particles’ size and drug loading efficiency. The obtained results 
have shown significant differences in loading, but not in size. 
Regarding nanofibers, these were prepared by Electrospinning, using Polycaprolactone. 
Nanofibers have not only the capacity of performing an efficient drug delivery, but they can 
also provide support as a scaffold. Different formulations regarding polymer concentration and 
the organic solvent were tested. However, due to the polymers’ degradation, this procedure 
could not be optimized. Therefore, further experiments on this topic should be performed. 
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CHAPTER 1 
 
Literature Review  
 
 
 
1.1. BONE 
1.1.1. General Considerations 
Bone is a complex and dynamic tissue with the ability to adapt to its functional demands 
and repair itself [1]. It is considered to be a connective tissue that functionally interacts with 
several other organs and tissues [2]. This tissue has an important role in mechanical (it supports 
the whole body and allows locomotion), protective (it shields vital organs and bone marrow) 
and metabolic (it acts in the regulation of calcium and phosphate homeostasis) functions [2]. In 
addition, bone is responsible for the storage of minerals and production of blood cells [3].  
In terms of classification, bones can be divided into flat, which corresponds to flat, slender 
and usually curved bones  (e.g. skull), long, which are classified as being longer than wider 
(e.g. femur), and short or cuboid, which are bones that are nearly as wide and thick as they are 
long (e.g. carpus) [3, 4].  
Bone is essentially made up of cells, extracellular matrix, which is mineralized, water and 
lipids. Regarding the cellular component, bone is formed by four different cellular interveners: 
the osteoblasts, with osteogenic functions, the osteocytes, that play a role as mechanosensors 
in bone remodeling, the bone-lining cells, that cover the bones’ surface, and the osteoclasts, 
with resorption functions [2, 5]. More details about the bone cells will be described in the next 
section. In what concerns the bone matrix, it is composed by 35% of organic components 
(mainly formed by fibers of collagen and proteoglicans) and 65% of inorganic component 
(mainly formed by hydroxyapatite) [2, 3]. Collagen is responsible for the flexible resistance, 
while the mineral components confer compression resistance, which allows the weight support 
[3].  
Structurally, it can be identified two types of bone: cancellous or trabecular and 
cortical or compact bone (Figure 1-A). Cancellous bone is the most active bone part in terms of 
growth, calcium homeostasis and hematopoiesis [4]. It is constituted by interconnected bone
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plates nominated trabeculae, between which there is free space that is filled with bone 
marrow and vessels. The trabeculae are constituted by several lamellae, being the osteocytes 
placed between them. As, usually, blood vessels cannot cross the trabeculae, the osteocytes 
can only reach nutrients from the canaliculi, which are the channels that associate the 
osteocytes in bone. Regarding the trabeculae surface, it is constituted by a cell layer, which is 
mainly composed by osteoblasts and few osteoclasts [3]. Its supportive functions occur mainly 
in locations where compression type of loading is predominant (e.g. in vertebral bodies) [4]. 
Cortical bone (Figure 1-B) is stronger, more static, thicker and with less free space than the 
cancellous one [3, 4]. The osteocytes and lamellae present in this type of bone are positioned 
around the blood vessels, which penetrate the bone mass. In fact, in cortical bone, there are 
two main channels where blood vessels penetrate: the channels parallel to the bone axis, which 
are called Havers or central channels, and the channels perpendicular to the bigger bone axis, 
which are called Volkmann or perforating channels. Furthermore, it can also be found in 
cortical bone the osteon or Havers system, which is constituted by a central channel and its 
content (which includes blood vessels, nerves and loose connective tissue), concentric lamellae 
and osteocytes. In fact, it can be distinguished three different types of lamellae present in 
cortical bone: the concentric lamellae, previously referred as being part of the osteon, which 
are concentric circular layers of bone matrix that round a common center (center channel); the 
circumferential lamellae, which are considered to be flat plates that form the external surface 
of cortical bone; and the interstitial lamellae, which are present between the osteons and 
consist of remaining of concentric or circumferential lamellae [3]. The main locations of 
cortical bone include the shafts of long bones and peripheral lining of flat bones [4].  
Microscopically, it can also be distinguished two types of bone, accordingly to their 
collagen fibers organization: the woven and the lamellar bone. In the woven bone the collagen 
fibers are randomly organized, in different directions. It is present in newborns and in places 
where fast bone formation occurs (e.g. after a fracture). The lamellar is considered to be the 
mature bone that organizes itself in thin layers of lamellae. In this case, the collagen fibers of 
each lamella are organized parallel to one another and angled to the collagen fibers present in 
the adjacent lamellae. The osteocytes are present in the interior of the gaps, between the 
lamellae layers [3, 4]. After the formation of woven bone, usually it is organized to become 
lamellar bone, in a process named remodeling [4]. Figure 2 schematizes the different types of 
bone at different structural levels, including the cellular level. 
 
 
BONE 
 
21 
 
 
 
Figure 1. Schematic view of human long (A) and cortical (B) bone. Adapted from [3]. 
 
(A) 
(B) 
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Figure 2. Overview of the different levels on bone structure. (A) Macroscopic aspect of a right femur, 
with special emphasis on the cortical and spongeous (trabecular) bones. (B) Cortical and the inner 
spongeous bone in detail, showing the trabeculae that compose the latter referred type of bone. (C) 
Single trabeculae with bone marrow cavities lined with endosteum on each side. (D) Woven type of bone. 
(E) Lamellar type of bone. (F) An example of osteoblast from woven bone. (G) An example of osteoclast 
from woven bone. (H) An example of an osteocyte and surrounding structures. Adapted from [3, 4]. 
 
 
 
(F) 
(G) 
(H) 
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1.1.2. Formation and Remodeling
Bone is continuously being renewed trough a dynamic balance between bone resorption and 
formation. This constitutes the central basis for the maintenance of normal bone mass and 
architecture and calcium homeostasis, which is mediated essentially by the osteoclasts 
(responsible for bone resorption) and osteoblasts (in charge of bone formation) [6].  
The bone cells mentioned in the previous section are divided into two main groups: 
osteoclasts and the osteoblastic family (which includes osteoblasts, osteocytes and bone lining 
cells) [6]. 
Osteoblasts derive from mesenchymal stem cells. An example of this type of cell is shown 
on Figure 2-(F). Osteoblasts have important functions in bone formation, as they are 
responsible for the deposition of the uncalcified bone matrix (named osteoid), and subsequent 
mineralization. This mineralization is reached in two steps: firstly, hydroxyapatite crystals are 
formed within the matrix vesicles; secondly, these mineral crystals are elongated into the 
extracellular space, filling gaps between collagen fibrils [2]. Moreover, another important 
function attributed to osteoblasts is the regulation of osteoclast differentiation, as osteoblasts 
produce important cytokines for this process [2]. At the end of the bone formation phase, 
osteoblasts have different fates: they can be subjected to apoptosis, become inactive 
osteoblasts or bone lining cells, or be trapped in the bone matrix as osteocytes [2]. Regarding 
the bone lining cells, they form a thin continuous layer that covers all bones’ surfaces, enabling 
a controlled movement of ions between the body and the bone. It is considered that the layer 
of cells located outside the bone is named periosteum (this term often includes the collagenous 
sheet that covers the outer surface); the cells’ layer placed on the inside of the bone, it is 
termed as endosteum (Figure 1-(A)) [5]. In what concerns the osteocytes (Figure 2-(H)), they 
correspond to the cells present in the body of the bone [5]. Although it is possible for them to 
produce essential components to maintain the bone matrix, compared to the osteoblasts, 
osteocytes are relatively inactive [3]. Osteocytes are trapped in the hard bone tissue, 
occupying free spaces called lacunae and connecting with neighboring osteocytes and bone 
lining cells through cellular prolongations in the canaliculi [3, 5]. Gases and nutrients can 
circulate through a small quantity of liquid that surrounds cells in the lacunae and canaliculi or 
by moving from cell to cell, through the gap junctions that join the cellular prolongations [3]. 
Osteocytes have different functions, from which can be highlighted their role as 
mechanosensors (they perceive mechanical strain variations and translate it into biochemical 
signals that will affect bone formation and/or resorption), the regulation of phosphate 
homeostasis and mineralization, and, in early studies, it was also suggested that osteocytes 
have the ability to regulate calcium homeostasis [2]. 
Osteoclasts are big and multinucleated cells that derive from the monocyte-macrophage 
line. An exemplificative image of these cells is represented on Figure 2-(G). Osteoclasts are 
responsible for bone resorption or destruction, which is conducted through two different 
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processes: the acidification to dissolve the inorganic matrix and the secretion of proteolytic 
enzymes that digest the organic compounds of the bone [2, 3, 5]. The first step occurs when 
the cellular membrane contacts with the bone matrix, leading to the formation of several 
projections that will give rise to a ruffled border. Hydrogen ions are pumped through this 
border, producing an acidic medium that decalcifies the bone matrix. In the second phase, 
osteoclasts release enzymes that digest the matrix protein components. Some of the products 
that result from this procedure are conducted to the osteoclast interior through an endocytosis 
process. Besides this procedure, osteoblasts can also interfere in the resorption process by 
degrading the non-mineralized organic matrix part. This step performed by osteoblasts allows 
the direct contact between the osteoclasts and the mineralized bone matrix, enabling a better 
degradation process [3].  
Bone cells mediate not only the formation, but also the bone remodeling. This process 
occurs in order to substitute the old bone by a new one. Therefore, osteoclasts remove the old 
bone through resorption processes, and later the osteoblasts deposit the new bone. During the 
remodeling, the woven bone will be substituted by the lamellar one, making it possible to 
accomplish different functions, including bone growing, changings in bone configuration, 
development of new osteons, adaptation to mechanical stress, calcium ions regulation and 
bone repair [3].  
Bone repair can be divided in two basic types: primary and secondary bone healing. Primary 
healing it is rare and corresponds to the attempt of cells in cortical bone to re-establish the 
disrupted continuity [7]. In the case of secondary bone healing, it has a characteristic sequence 
of events that include hematoma, inflammation, formation of soft and then hard callus and 
remodeling [7]. In the case of, for example, a fracture, there is a disruption of the local tissue 
integrity, interruption of normal vascular function and distortion of the marrow architecture [3, 
7]. This usually leads to the formation of a hematoma with sequential release of inflammatory 
mediators. This response is characterized by the same steps that occur in other injured tissues: 
increased blood flow, vascular permeability, migration of inflammatory cells and release of 
cytokines, and activation of the complement cascade [7]. Consequently, there is a formation of 
a soft callus, which is a cartilaginous callus. Although it is initially avascular, its subsequent 
replacement with woven bone involves vascular invasion [3, 7]. The hard callus formation is 
characterized by an active stage of osteogenesis, osteoblastic activity and formation of 
mineralized bone matrix. During the formation of the hard callus, the soft callus is gradually 
removed as revascularization occurs [7] and woven bone is formed [3]. These steps are similar 
to the ones that occur in endochondral and intramembranous bone formation, which are the 
processes responsible for skeletogenesis [4, 8]. In fact, the formation of the hard callus can be 
associated to endochondral bone formation, while the intramembranous bone formation is 
responsible for the formation of compact or more spongeous cancellous bone [4]. The final 
process in bone repair will correspond to bone remodeling, which was previously described. 
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In the clinical setting, the most common form of bone regeneration occurs in fracture 
healing, which is a specific case of bone repair [8]. However, in some cases, like in large bone 
defects, the normal biological procedure of regeneration is not enough, what leads to the need 
of an external help.  
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1.2. NPY SYSTEM IN BONE REMODELING 
1.2.1. NPY Y1 Receptor  
Neuropeptide Y (NPY) is a 36-amino acid neurotransmitter [9-12]. that was first isolated 
from pig brain by Tatemoto et al. [13]. NPY is abundantly expressed in several brain regions [9, 
10, 12] with the highest expression occurring in the hypothalamic arcuate nucleus [9, 12, 14]. 
In the periphery, the adrenal medulla is the primary source of circulating NPY but this 
neuropeptide is also expressed in liver, heart, spleen and endothelial cells of blood vessels 
[10], as well as on vascular smooth muscle cells, pancreatic cells, periosteum, bone marrow 
(particularly in megakaryocytes) [15] and in osteoblasts, osteocytes [9, 12, 15], chondrocites 
[15], and osteoclasts (unpublished data) [9, 12]. It is also present in the sympathetic nervous 
system, being co-stored and co-released with noradrenaline upon nerve stimulation [9, 10]. In 
what concerns the function, NPY is known to play major roles in food consumption regulation, 
blood pressure, anxiolysis induction, memory retention, circadian rhythms and energy 
homeostasis [1, 11, 16]. Besides all of these, the discovery of NPY-immunoreactive fibers in 
bone tissue, associated to blood vessels, bone lining and bone marrow cells [17], indicates that 
NPY has a central role in regulating bone homeostasis, by performing neuroendocrine actions on 
bone cells [1, 12].  
NPY functions are exerted throughout 5 NPY receptors, termed as Y receptors Y1, Y2, Y4, 
Y5 and Y6 [1, 9, 12, 18]. From these, so far only Y1 and Y2 were found to play a role in the 
regulation of bone homeostasis (Table I). 
Y2 receptors are expressed in several areas of the brain, such as the hypothalamus, 
hippocampus, amygdala and brain stem [9, 12, 16]. Peripherally, the Y2 receptors are 
expressed in white and brown adipose tissue, liver, muscle, spleen and intestine, but not in 
osteoblasts [9, 12]. The definitive evidence that NPY plays a role in the regulation of bone 
homeostasis was first revealed by Baldock et al. [19] after germline deletion of Y2 receptors in 
mice [20]. The results obtained from this deletion shown an increase in cancellous bone 
volume, which was associated with an amplified osteoblastic activity [19]. Likewise, selective 
deletion of hypothalamic Y2 receptors in mice resulted in an identical increase in trabecular 
bone volume within 5 weeks [19]. As no changes of circulating hormones were detected during 
the experiments, the modulation of bone formation was attributed to the hypothalamic Y2 
receptors through neural mechanisms. In addition to this, it was observed that whereas in wild 
type bone marrow stromal cells Y1 expression was detected (but Y2, Y4, Y5 and Y6 expression 
was absent), in Y2 knockout bone marrow stromal cells it wasn’t detected any Y receptors 
expression [21]. This was further evidence that the resulting observable effects on bone were 
related to Y2 central mechanisms, which were probably associated to changings in the Y1 
receptor, and not by direct mechanisms in bone cells [19, 21]. 
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Table I. Summary of bone phenotypes from mice after deletion of Y receptors. For Y5 and Y6 
receptors there aren’t reported conclusions.  
Gene 
Deletion 
 
Y1 (G) 
[18, 21] 
 
Y1 (Hyp) 
[18] 
 
Y1 (C) 
[22] 
 
Y2 (G) 
[19] 
 
Y2 (Hyp) 
[19] 
 
Y4 
[23] 
 
Y2Y4 
[23] 
 
Y1Y2 
[18] 
 
Cancellous 
bone 
volume 
↑ ↔ ↑ ↑ ↑ ↔ ↑↑ ↑ 
 
Cortical 
bone mass 
↑ ↔ ↑ ↑ ↑ ↔ ↓ ↑ 
Osteoblast 
activity 
↑ ↔ ↑ ↑ ↑ ↔ ↑ ↑ 
 
Osteoclast 
surface 
↑ ↔ ↑ ↔ ↔ ↔ ↑ ↔ 
 
G – Germline Knockout; C- Conditional Knockout; Hyp – Hypothalamus Knockout; 
 ↑ - Increased; ↔ - Unaltered; ↓ - Decreased. 
 
Regarding Y1 receptors, they have the widest distribution in the brain, being expressed in 
cerebral cortex, thalamus, amygdala [11, 16] and particularly in the paraventricular nucleus 
(PVN) of the hypothalamus [9, 12]. Also, Y1 receptors have a broad distribution in peripheral 
tissues, including colon, pancreas, adipose tissues, kidney adrenal gland, heart, placenta and, 
regarding the bone, Y1 receptors are so far the only ones found to be expressed in the 
osteoblastic lineage and bone marrow stromal cells [12, 15]. In order to evaluate how Y1 
receptors knockout would directly influence bone homeostasis, Lundberg et al. [21] performed 
a study using germline Y1 receptor knockout mice and it was concluded that the alteration of 
the Y1 receptor signaling leads to a modification in bone formation, as the germline deletion of 
Y1 receptors resulted in greater bone mineral content and bone mineral density. The same 
results were obtained by Baldock et al. [18], who demonstrated that the resulting greater bone 
volume in germline Y1 receptor knockout mice was associated with both osteoblastic and 
osteoclastic activity. In fact, the results showed that, besides bone formation and unlike what 
happened in the Y2 receptor knockout studies, bone resorption was also altered in germline Y1 
knockout mice, with significant greater osteoclast surface. However, when a hypothalamus-
specific deletion of Y1 receptors was performed, the achieved results exhibited no alterations 
in bone volume neither in bone cell activity when compared to the control group. This led to 
the conclusion that the Y1 receptor regulates bone homeostasis by a peripheral, non-
hypothalamic, pathway. Therefore, with this new insight, new studies have been made in order 
to evaluate the potential of peripheral Y1 receptors knockout as a new therapeutic strategy on 
bone metabolism. Lee et al. [24] experiment demonstrated that osteoblastic-specific Y1 
deletion resulted in elevated osteoblast activity in male mice, increasing cancellous and 
cortical bone mass. This suggested that Y1 receptors would be a potential target to treat bone 
associated diseases. In keeping with this, Sousa et al. [22] showed that the oral administration 
of a Y1 receptor antagonist to wild type mice resulted in increased bone mass, with high 
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mineral apposition rate in both cortical and cancellous bone of mice. However, besides this, it 
was observed an increase in bone resorption indices, which was a behavior only observed in 
germline deletion of Y1 receptors. This result suggested that Y1 receptor blockage would not 
only lead to elevate bone mass, but could also lead to an adequate bone turnover, thereby 
possibly avoiding hypocalcaemia and related complications [22]. 
As previously referred, there is an Y2-dependent inhibition of Y1 expression in osteoblastic 
lineage cells that suggests the existence of a mechanism where central Y2 signaling moderates 
tissue homeostasis [18, 21]. Likewise, the osteoblastic effects from Y1 knockout and Y2 
knockout were similar. Therefore, there was the hypothesis that these two receptors were 
linked in the regulation of bone homeostasis [18]. In order to evaluate this supposition, in the 
same study previously referred, Baldock et al. [18] performed a germline Y1Y2 double 
knockout. However, the results showed that deletion of both Y1 and Y2 receptors did not result 
in additive effects on bone mass when compared to Y1 knockout and Y2 knockout mice. Thus, it 
was concluded that, although Y1 and Y2 appear to share common pathways in the regulation of 
bone tissue, there are discrete actions of individual Y receptors, with probable central Y2 and 
peripheral Y1 effects on bone tissue [15, 18]. 
Therefore, in order to explore the potential of Y1 receptors, several Y1 receptor antagonist 
strategies have been investigated in Y1 receptor targeting therapies for diseases such as 
anxiety [25-31], obesity [32-40], epilepsy [41, 42], between several others. Thus, several 
effective Y1 receptor antagonists are commercially available in order to determine the 
pharmacological role of Y1 receptors in targeted diseases. 
1.2.2. Anti Y1 Receptor Therapeutic Strategies 
The Y1 receptor has a great range of peptide and non-peptide antagonists available. These 
antagonists have been applied in several experiments, with different purposes. In Table II a 
summary of the available Y1 receptor antagonists, therapeutic applications and obtained 
results with the respective administration methods is presented.
 
Table II. Summary of the peptide and non-peptide antagonists for Y1 Receptor and some of the 
respective studied applications and results.  
Antagonists 
Target 
Therapy 
 
Results 
Administration 
Method 
References 
BIBO3304 Anxiety  Attenuation of anxiolysis 
in the feeding tests, but 
not in the shock-probe 
ones 
Infusion [31] 
 Inhibition of the anxiolytic 
effect 
Injection [30] 
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Bone Mass  Dose-dependently increase 
in bone mass 
Oral [22] 
Depression  Attenuation of the 
antidepressant-like effects 
Injection, Infusion [43, 44] 
Inflammatory 
Response 
 Abolition of the pro-
inflammatory action 
Injection [45] 
Food Intake  Inhibition of feeding 
behavior  
Injection, Injection [39, 40] 
Pain 
Modulation 
 Prevention of the anti-
allodynic actions 
Injection [46] 
Post-Traumatic 
Stress Disorder 
 Prevention of the 
inhibition of fear 
responses 
Infusion [47] 
BIBP3226 Anxiety  Potentiation of the 
anxiogenic and depressive 
effects of Cholecystokinin 
tetrapeptide 
Injection [25] 
 
 
 
 Induction of an 
anxiogenic-like effect 
Injection, Injection, 
- 
 
[26-28] 
Atherosclerosis  Increased atherosclerotic 
lesion areas 
Injection [48] 
Depression  Attenuation of the 
antidepressant-like effects 
Injection [43] 
Epilepsy  Reduction of the number 
and time of seizures 
Infusion [41] 
Heart 
Associated 
Functions 
 Dose-dependent inhibition 
of the increase in blood 
pressure 
 
- , Infusion [49, 50] 
 
 No significant change in 
heart rate 
 Smaller infarct volume 
 
Injection [51] 
 Inhibition of the 
vasoconstriction 
-, In vitro, Infusion, 
In vitro, In vitro 
[49, 52-55] 
Hypothalamic-
Pituitary-
Adrenal 
Regulation 
 The increase of plasma 
corticosterone levels was 
contradicted 
Infusion [56] 
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Microglial 
Reactivity 
 Suppression of the 
reduction of interleukin-
1β and tumor necrosis 
factor-α protein 
generation  
In vitro [57] 
Food Intake  Inhibition of food intake Injection, Injection [36, 38] 
Renal Function  No influence in renal 
functions in ischaemic 
heart failure rats 
Infusion [50] 
Reproductive 
Function 
 Inhibition of the increase 
of Gonadotropin-Releasing 
Hormone-1 mRNA 
In vitro [58] 
GI264879A  Food Intake  Decrease in food intake 
and body weight 
Injection [32] 
GR231118 Anxiety  Decrease in time spent in 
social interaction 
(increased anxiolysis) 
- [27] 
Epilepsy  Reversion of the 
anticonvulsant effect of 
intrahippocampal ghrelin 
Microinjection [42] 
Depression  Increased depression-like 
behavior 
Injection [59] 
Heart 
Associated 
Functions 
 Inhibition of both cardiac 
slowing and decrease in 
arterial pressure 
 Increase in ventilation 
Injection [60] 
Food Intake  Decrease in food intake 
stimulated by orexin 
Injection [34] 
Vascular 
Secretory 
Function of 
Salivary Glands 
 Inhibition of the 
attenuation of 
vasodilation 
 Inhibition of the pressor 
response 
Injection [61] 
H409/22 Anxiety  Increase the anxiolytic-
effect 
Injection [29] 
Colitis   Attenuation of the clinical 
manifestation of the 
disease 
Injection [62] 
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Food Intake  Suppress of food intake  Infusion [37] 
Heart 
Associated 
Functions 
 Inhibition of the 
vasoconstriction 
Infusion [63] 
J-104870 
 
Food Intake  Suppress of food intake Injection [35] 
J-115814 Food Intake  Suppress of  food intake 
and body weight 
Oral [64] 
LY357897 
 
Food Intake  Suppress of food intake Injection [33] 
SR120819A  Food Intake  Dose-dependent reduction 
of food intake 
Injection [39] 
Heart 
Associated 
Functions 
 Attenuation of 
vasoconstriction on the 
kidney 
- [65] 
Lipolysis and 
Leptin 
Secretion 
 Blockage of the 
antilipolytic efect evoked 
by hPYY 
 Prevention of adipocyte 
leptin secretion 
In vitro [66] 
 
(-) Corresponds to administration methods with unknown information.  
 
BIBO 3304 is the abbreviation for N-[[4-(Aminocarponylaminomethyl)-phenyl] methyl]-N2-
(diphenylacetyl)-argininamide trifluoroacetate. This non-peptide compound exhibits selective 
binding to the Y1 receptor subtype, with more than 1000 to 10000-fold lower affinity for human 
Y2, human and rat Y4 and human and rat Y5 receptors. Likewise In what concerns its properties 
to inhibit the NPY mediated signals, no agonistic properties were found to BIBO3304. Thus, it is 
considered that BIBO 3304 is a potent Y1 receptor antagonist [40] and, when compared to BIBP 
3226, it has a 10-20 fold higher affinity for both human and rat Y1 receptors [67]. However, this 
compound isn’t available in radiolabelled form [68]. Chemically, it presents a molecular weight 
of 757.69. 
BIBP 3226 corresponds to the short name for R-N2-(Diphenylacetyl)-N-(4-hydroxyphenyl)-
methyl argininamide. It corresponds to a non-peptide Y1 receptor antagonist, exhibiting 
competitive and excellent Y1 receptor selectivity [49, 69], as it doesn’t bind to human Y2 
receptor subtype nor cross-react to 60 other experimented receptor types and 15 enzyme 
systems [70]. BIBP3226 doesn’t reveal agonistic properties towards Y1 receptors [69, 70] and 
therefore it is considered to be the first true non-peptide Y1 receptor antagonist, with 
characteristics that make it a suitable tool to study the role of NPY in pathophysiological 
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conditions [70]. This compound has shown to be a fully antagonistic for both neural cells and 
peripheral tissues [71]. Chemically, BIBP3226 is a hydrophobic compound with a molecular 
weight of 473.57. 
Regarding GI264879A, it is an abbreviation for 1-Substituted-4-methylbenzimidazole (413), 
N--[3,3-bis(1-naphthyl)propionyl]-D-arginine N-[(S)-1-benzyl-2-methoxyethyl] amide. It is 
considered to be a non-selective and weak NPY receptor ligand, with decreasing affinity for Y1 
(which is equal for the Y4), Y5 and Y2 receptors. Regarding its behavior towards NPY mediated 
signals, GI264879A was tested only for the Y1 receptor and it showed antagonistic properties 
[32]. 
GR23118, also named GW1229 or 1229U91, is the abbreviated name for Homodimeric Ile-
Glu-Pro-Dpr-Tyr-Arg-Leu-Arg-Tyr-CONH2. Although this peptide compound reveals potent Y1 
receptor antagonistic properties, it was discovered that GR23118 is also an agonist for Y4 
receptors [72]. Regarding the compound chemistry, it has a molecular weight of 2352.77. 
In what concerns H409/22, it corresponds to the abbreviation of the (2R)-5-
([Amino(imino)methyl]amino)-2-[(2,2-diphenylacetyl)amino]-N-[(1R)-1-(4-hydroxyphenyl)ethyl 
]-pentanamide compound. H409/22 is considered to be a potent and selective ligand to Y1 
receptors, with antagonistic properties and very low affinity for Y2 and Y5 receptors. However, 
this compound reveals 5 times lower potential than BIBO 3204 [37]. The molecular weight of 
this non-peptide compound is approximately 487.61.  
J-104870 is the abbreviation for 2-[(4-Chlorophenoxy)methyl]benzimidazoles (411), 6-(5-
ethyl-1,3-thiazol-2-ylthiomethyl)-2-[3-methoxy-5-(2-propenyloxycarbonylamino) benzylamino] -
4-morpholinopyridine. This compound corresponds to a potent and selective antagonist for the 
Y1 receptor, revealing low affinities for Y2, Y4 and Y5 receptors. Besides this, it is considered 
that this non-peptide compound has oral bioavailability and brain penetrability [35]. Its 
molecular weight is approximately 555.72. 
In what concerns J115814, it is the abbreviation for (-)-2-[1-(3-chloro-5-isopropyl 
oxycarbonyl aminophenyl) ethylamino] -6-[2-(5-ethyl-4-methyl-1,3-thiazol-2-yl)ethyl]-4-
morpholinopyridine. This compound has a high affinity to Y1 receptors, but low affinity for Y2, 
Y4 and Y5 receptors, what reveals its potent and selective Y1 receptor antagonistic properties 
[73]. 
LY357897 corresponds to the 1-((1-[3-((3s)(3-Piperidyl))-propyl]-2-[(4-chlorophenoxy)-
methyl]indol-3-yl]-2-(4-piperidylpiperidyl)ethan-1-one compound. At the time of its discover, it 
was classified as being the first selective, subnanomolar Y1 antagonist [33], as it doesn’t show 
appreciable binding affinity for Y2, Y4 and Y5 receptors [71]. 
Regarding SR120819A, it corresponds to the (2R)-N-[(2R)-3-[4-[N'-[[4-(dimethylaminomethyl) 
cyclohexyl] methyl] carbamimidoyl] phenyl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]-2-(naphthalen-
2-ylsulfonylamino)-3-phenylpropanamide compound. It is considered to be a non-peptide, orally 
active and selective Y1 receptor antagonist [74, 75], as it did not reveal affinity for Y2, Y4 or 
Y5 receptors [71]. SR120819A has a molecular weight of 750.39. 
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1.3. DRUG DELIVERY SYSTEMS TO BONE 
1.3.1. Current Therapeutic Approaches for Bone 
Regeneration 
For situations where normal bone regeneration is impaired or insufficient, there are 
currently several therapeutic approaches that, when used alone or in combination, aim the 
enhancement or management of these complex clinical situations [8]. 
Bone grafting is a common surgical procedure used to enhance bone regeneration [8]. Bone 
grafting can be defined as being a strategy where bone from somewhere else is applied in the 
place where it is needed a stimulation of bone formation. There are three possibilities of bone 
grafting, being the preferable one the autologous bone graft (the used bone is the patient’s 
own, being usually harvested from locations with relative excess of bone, like the pelvis). The 
other two options of bone grafting correspond to the allogenic bone graft (the harvested bone 
belongs to other humans) and the xenogenic bone graft (the used bone graft belongs to other 
animals from other species) [4]. The autologous bone graft is considered to be the gold 
standard bone grafting material, as it comprises several advantageous properties: 
osteoinduction (the extracellular matrix contains bone morphogenetic proteins and other 
growth factors), osteogenesis (the graft contains osteoprogenitor cells that will contribute to 
bone formation after the graft is vascularized) and osteoconduction (it works as a scaffold that 
allows the deposition of bone and integration by the surrounding bone) [4, 8, 76]. Besides this, 
the autologous bone graft is histocompatible and non-immunogenic, reducing the probabilities 
of immunoreactions and transmission of infections [8]. Likewise, it can be completely resorbed 
and remodeled, not interfering with physiologic bone adaptation [4]. However, it presents some 
disadvantages, as for example limited mechanical strength, quantity restrictions, diverse 
physical injuries that arise from surgical complications and substantial costs [4, 8, 77]. As an 
alternative to autologous bone graft, allografts and xenografts were also thought as possible 
options. The allografts are obtained from human cadavers or living donors. This type of graft 
surpasses the problems of quantity, as allogeneic bone is available in many preparations [8]. 
However, as they are devitalized and sometimes demineralized, they do not possess any 
cellular component, what leads to reduced osteogenic and osteoinductive properties and, 
consequently, to a delay in the regeneration process [4]. Furthermore, this type of grafts is 
commonly associated to immunogenicity and rejection reactions and cost problems [4, 8, 78]. 
In what concerns the xenografts, they are obtained from animals of other species. However, 
several problems associated to ethics and graft rejection are attributed to this type of graft. 
As grafts present several disadvantages, bone-graft substitutes have been developed in the 
field of bone tissue engineering. These substitutes, named scaffolds, are made of natural or 
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synthetic biomaterials and aim to promote migration, proliferation and differentiation of bone 
cells [8]. In order to achieve these goals, bone tissue engineering usually combines scaffolds 
with biologically active factors, which can be cells, proteins or a combination of both. By doing 
this strategy, osteoconduction, osteoinduction and osteogenesis are reached. Thus, it becomes 
necessary to define three different components: scaffolds, growth factors and cells [4]. 
Scaffolds serve as a delivery vehicle for osteoinductive molecules and/or osteogenic cells. It 
must fill a gap in a bone defect, facilitating, at the same time, the healing process. However, 
to perform its purposes, scaffolds for bone regeneration must be biocompatible, 
osteoconductive, porous (the material must have an interconnected porous architecture in 
order to facilitate the bone growth inside of the material), biodegradable (this characteristic 
depends on the final aim of the scaffold, but usually, as bone is regenerated, the material must 
gradually degrade) and intrinsically osteoinductive [4]. Likewise, scaffolds must have good 
mechanical properties [4, 8]. In what concerns growth factors, they correspond to signaling 
molecules that influence certain cellular functions as they bind to specific receptors in cell 
membranes [4]. The most extensively studied molecules are the bone morphonegenetic 
proteins (BMPs), which correspond to potent osteoinductive factors [4, 8]. Other growth factors 
have also been used in different strategies, with different functions regarding cell proliferation, 
chemotaxis and angiogenesis. These include platelet-derived growth factors, transforming 
growth factor-β, insulin-like growth factor-1, vascular endothelial growth factor and fibroblast 
growth factor, among others [8]. Regarding the cellular component, an adequate supply of 
cells, such as mesenchymal stem cells (MSCs) and osteoprogenitors, is of major importance in 
bone regeneration strategies. Usually, these cells are obtained from the bone-marrow, which 
also contains growth factors, in a minimally invasive procedure [8].   
Besides the aforementioned strategies, gene therapies are rising as potential procedures to 
improve bone regeneration. This method involves the transfer of genetic material into the 
genome of the target cells, in order to promote the expression of bioactive factors for a 
prolonged time. However, to apply gene therapies, issues of cost, biological safety and efficacy 
problems must be solved [8]. 
In some cases, drugs can also improve bone regeneration. An ideal drug for bone 
regeneration should restrict its pharmacological activity specifically to bone sites, with minimal 
effects at a systemic level [79]. However, these drugs are usually administrated alone, orally or 
parenterally. As bone is a peripheral tissue with limited blood supply, during their pathway, 
drugs are exposed to various phsycochemical and biological factors, which will affect the drugs 
bioavailabilty and, thus, their efficient delivery to the required sites. In order to overcome this 
problem, larger drugs doses are administrated, leading to toxicity problems [80, 81]. Other 
complications may also arise from the fact that some drugs need to be taken for prolonged 
duration, resulting in problems associated with the patient therapy compliance [81]. Therefore, 
new agents and efforts should be made in order to develop new strategies that overcome the 
DRUG DELIVERY SYSTEMS TO BONE 
 
35 
 
abovementioned problems, enabling improvements in drug efficiency. An example of strategy 
that has been developed is the controlled drug delivery systems, which make use of different 
materials with different configurations (e.g. microspheres and nanoparticles). These new 
developed systems, to be considered as a drug carrier, must be non-toxic (i.e. bioinert or 
biodegradable), biocompatible, able to incorporate a drug physically or chemically and retain it 
until it reaches a specific target site, where the drug carrier will gradually be degraded and 
deliver the drug in a controlled way over time [82]. The materials from which drug carriers are 
made of, will be chosen accordingly to the desired characteristics, which include chemical 
characteristics (hydrophobicity or hydrophilicity, molecular size, pi, between others), desired 
delivery rate, drug release mode, target bone/bones, injury size, whether materials 
degradation is desired, between other parameters, such as carrier size and structure and drug 
loading [83, 84]. Therefore, through the combination of different parameters and materials, it 
is possible to develop new ways of drug delivering, enabling improvements in the field of bone 
regeneration.  
Drug delivery systems can be divided into systemic or local drug delivery. The systemic drug 
delivery systems are less invasive and usually associated to an oral or parenteral 
administration. However, these systems can provoke some side effects on non-skeletal tissues 
[85]. Also, the drugs used in this type of delivery systems should have prolonged circulation 
time, be able to distribute and accumulate on the target tissues and also they should be 
protected from enzymatic and chemical degradation [86]. Although it is a more invasive 
procedure, local delivery of drugs has some advantages towards the systemic drug delivery, as 
the needed drug quantity is reduced, the side effects are lower, drugs can be retained in the 
specific local for increased periods and it allows a time-controlled deliver. Ideally, this local 
drug delivery process should deliver the drug through minimally invasive procedures (e.g. 
injection to the local site) and possess the ability for in situ matrix formation, allowing an 
accelerated wound healing, ease in the recognition of requirements of irregular shape defects 
and augmented patients’ comfort and compliance [87, 88].  
Therefore, several approaches can be studied in order to improve the actual solutions used 
to bone regeneration, with special attention to the drug delivery systems.
1.3.2. Nanoparticles Drug Delivery Systems 
Nanoparticles have become an important area in the drug delivery systems field as they 
have the ability to deliver a wide range of drugs to different areas of the body for sustained 
periods of time, while their small size makes them suitable for systemic circulation [89]. 
Recent advances in synthesis of polymeric materials with enhanced and advantageous 
characteristics (biocompatibility, controlled biodegradation profile and responsiveness to 
biologically-relevant stimuli) are leading to the development of new drug delivery systems [90]. 
These nanocarriers are divided into two categories: nanocapsules (vesicular system with a 
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polymeric shell and inner core) and nanospheres (polymeric matrices) [84]. Nanocapsules differ 
from nanospheres in their constitution: nanocapsules are used in a reservoir form, in which a 
solid material surrounds a core which is liquid or semisolid at room temperature; nanospheres 
are matrix particles, which means that their entire mass is solid [91]. In both cases, 
nanoparticles can be loaded with a wide variety of drugs, including hydrophilic and hydrophobic 
drugs, proteins, vaccine and biological macromolecules [89]. Drugs can be entrapped inside the 
nanoparticles or adsorbed on their surface. The first option can be performed by an association 
of the drug and the nanocarrier during the preparation of the nanoparticles; for drugs that are 
highly susceptible to degradation, the adsorption on the surface of the nanoparticles becomes a 
more suitable procedure [91]. 
There are several methods for the preparation of nanoparticles that allow the production of 
polymeric nanoparticles with different properties that ensure a proper drug delivery and 
targeting. These methods can be divided in procedures that include two main steps and the 
ones that include only one main step. The two steps methods comprise the preparation of an 
emulsified system (first step), followed by the nanoparticles formation (second step). Usually 
the second step is achieved either by precipitation or gelation of a polymer or polymerization 
of monomers. The methods that only require one step are based on the precipitation of a 
polymer in conditions of spontaneous dispersion formation or due to the self-assembly of  
macromolecules to form nanogels or polyelectrolyte complexes from a polymeric solution [91]. 
As nanoparticles have the same size range as parts of natural bone, they are considered as 
potential candidates for local applications as bone-specific carriers [82]. Furthermore, 
nanoparticles offer other several advantages, including controlled release properties, 
protection to the compound of interest and possibility of changing the nanoparticles surface for 
actively targeting them to specific desired tissues [84, 90]. In order to achieve the desired 
results, as previously mentioned in section 1.3.1, nanoparticles should comprise a set of 
characteristics: be nontoxic for cells, effectively carry the molecule of interest and exert their 
actions specifically on the target, therefore reducing the side effects systemically [82]. 
As also mentioned in the previous section, the main criteria in choosing a material for drug 
delivery include not only the chemical characteristics of the drug to be delivered, but also 
bioavailability, biocompatibility, straightforward production and degradation rate, which 
enables a sustained release of drugs encapsulated in nanoparticles [84]. Therefore, it becomes 
essential to perform a previous study on the required delivery parameters and available 
materials and correspondent characteristics. 
1.3.2.1. Polycaprolactone, Poly(lactide-co-glycolide) and 
Monoethoxy poly(ethylene glycol)-poly(trimethylene 
carbonate) Polymers 
Polymers are versatile materials that can be useful in several applications. For example, 
hydrophilic polymeric nanoparticles can be applied and used for hydrophilic drugs, gene, 
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oligonucleotides and small interfering RNA; on the other hand, hydrophobic polymers can be 
used for water-insoluble drugs [90]. Usually, biodegradable polymeric nanoparticles are 
preferred as they enable controlled/sustained release, subcellular size and biocompatibility 
with tissues and cells. Furthermore, these compounds are stable in blood, non-toxic, 
biodegradable, nonthrombogenic, nonimmunogenic, noninflammatory, do not activate 
neutrophils and avoid reticuloendothelial system [92]. Polycaprolactone (PCL), Poly(lactide-co-
glycolide) (PLGA) and Monoethoxy poly(ethylene glycol)-poly(trimethylene carbonate) (mPEG-
PTMC) were previously tested in our group in nanoparticles’ preparation procedures [93]. 
Therefore, a revision on these three polymers was performed in order to understand their 
characteristics and suitability for the proposed theme.  
PCL has a hydrophobic nature [90]. In physiological conditions, this polymer degradation 
occurs by hydrolysis of its ester linkages. PCL receives a special attention for the preparation of 
long-term implantable devices [92], as it has a degradation rate of 2 to 3 years, low tensile 
strength and very high elongation ate breakage [94]. It is also considered to be a semi-
crystalline polyester with great organic solvent solubility [94]. Regarding its applicability, PCL 
has been used as a drug carrier in several studies, including anticancer, diabetes (insulin), 
antifungal (amphotericin B) and clonazepam drugs [92]. However, so far, no PCL nanoparticle 
delivery system to bone has been reported. 
PLGA corresponds to a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA). PLA 
is more hydrophobic than PGA and, consequently, lactide rich PLGA copolymers are less 
hydrophilic, adsorb less water and degrade more slowly. In fact, the 50:50 ratio of PLA/PGA 
exhibits the highest rate of degradation; for other ratios, as the content of PGA is higher, the 
degradation rate also augments [95]. After hydrolysis, PLGA produces metabolite monomers 
(lactic and glycolic acid), which are two monomers with which the body usually deals. 
However, the acidic nature of this copolymer makes it not suitable for drugs or bioactive 
molecules. This problem can be overcome by blending the PLGA with other compounds [92]. In 
what concerns the mechanical strength, swelling behavior, capacity to undergo hydrolysis and 
biodegradation rate are dependent on the PLGA physical properties (molecular weight, 
polydispersity index and cristallinity) [95]. This polymer has been widely used to encapsulate 
and deliver several types of drugs, including anticancer, diabetes (insulin), psychotic, hormonal 
(estradiol) and tetanus drugs [92]. Regarding specifically the targeting to bone, drug delivery 
systems based on PLGA micro and nanoparticles have been developed and used as carriers for 
recombinant human morphogenetic protein-2 (rhBMP-2) [96, 97], recombinant human bone 
morphogenetic protein-7 (rhBMP-7) [98], transforming growth factor β (TGF-β) [99], nafcillin 
[100], estrogen [101] and dexamethasone [102]. 
mPEG-PTMC is a diblock copolymer and it is considered to be an amphiphilic compound: the 
mPEG component constitutes the hydrophilic part, while the PTMC segments are the 
hydrophobic ones [103, 104]. It degrades very slowly in water and in acidic environments, 
although in lipase solutions it can be degraded by an enzymatic surface erosion process [104]. 
In fact, block copolymers containing PEG have been widely used for the development of 
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controlled delivery systems of drugs. On the other hand, as PTMC doesn’t form acidic 
compounds during its degradation by surface erosion, PTMC-based polymers are also very 
attractive for the delivery of drugs [104]. The use of this copolymer has been widely described 
by Zhang et al [104] in several studies regarding the compound characteristics and its use in the 
preparation on micro and nanoparticles. However, besided the aforementioned studies, mPEG-
PTMC has not been described in literature.  
1.3.2.2. Nanoparticle Delivery Systems for the Extracellular 
Space 
The cell membrane acts as a barrier or biomembrane that separates the external 
environment from the inside of the cell. Understanding interactions between particles and this 
membrane becomes important to predict subsequent biological effects [105].    
Internalization of nanoparticles in cells is influenced by several physical and chemical 
properties of the materials, as well as by the medium characteristics in the moment of the 
exposure. There are several nanoparticle characteristics that influence their uptake: size, 
shape and geometry, surface charge and hydrophilicity. The bulk characteristics of the 
nanoparticle do not play an important role in the particles internalization, as the surface 
characteristics are the ones that determine the protein corona and therefore biological impact 
[106].  
Several studies have been made with the aim of evaluating how the particles size can 
influence their uptake by cells. Accordingly to Sylvester et al. [107], nanoparticles of 100 and 
200 nm were easily internalized by cells, while particles with 500 nm remained in the 
extracellular space. Thus, it was concluded that 350 nm would be the ideal size to retain the 
nanoparticles in the extracellular space. Same results were obtained by Sivaraman and 
Ramamurthi [108], who also concluded that, although 500 nm size particles are completely 
excluded by cells, in certain cases they can be phagocyted. These results are in agreement with 
several others that demonstrate that nonphagocytic cells favor the uptake of smaller particles 
while larger particles aren’t internalized by these same cells [109-114]. However, there isn’t 
agreement in which is the exact size that leads to the exclusion of the particles by 
nonphagocytic cells [114]. Regarding the phagocytic cells, although some results have shown 
that there is a particle size-dependent uptake [115], there isn’t clear evidences that this 
procedure is unequivocally related to particle size [106]. 
Regarding the shape and geometry, Gratton et al. [114] studied the uptake of monodisperse 
cross-linked PEG hydrogel particles by HeLa cells. The results showed that cylindrical 
nanoparticles with high-aspect-ratio (diameter (d)=150nm, height (h)=450nm) were internalized 
faster than the symmetric (aspect-ratio (AR)=1, d=h=200 nm) cylindrical nanoparticles, 
although they have the same volume. When comparing cylindrical nanoparticles with similar 
aspect ratio but different diameter (d=100nm vs d=150nm), the results indicated that the 
particles with smaller diameter were less internalized than the larger ones. The same happened 
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to cubic particles, as the ones with lower side length were more internalized than the larger 
particles. Huang et al. [98] obtained the same results with mesoporous silica nanoparticles 
(MSNs) and A375 human melanoma (A375) cells, as particles with smaller AR had minor 
interaction with cells. However, these results were contradicted by Chithrani et al. [111], as 
the reported study showed that lower aspect-ratio led to greater cellular uptake. In order to 
also evaluate the effect of the particles geometry in phagocytosis, Champion and Mitragotri 
[116] used polystyrene particles with different geometries (spheres, oblate ellipsoids, prolate 
ellipsoids, elliptical disks, rectangular discs and UFOs) and studied their internalization by 
macrophages. All shapes were effective in initiating the phagocytosis process in, at least, one 
orientation. However, this internalization was dependent on the local particle shape, i.e., by 
measuring tangent angles, it was possible to analyze that the point of initial contact between 
the particles and the macrophages dictates if the particles will be phagocytized or if 
macrophages will spread on particles. Here, the particle volume was also an important 
parameter, as particles larger than cells led to a non-complete phagocytosis. Therefore, there 
isn’t a common sense on which shapes will give rise to the particles uptake, as it is necessary to 
consider length, diameter and volume of the particles. Likewise, there aren’t any clear 
evidences of which of these parameters is dominant [106] and, thus, fair conclusions about 
shape and geometry cannot be taken. 
Surface charge has been also studied as an important parameter that regulates the particles 
uptake. To this parameter, studies are more consensual, as the majority of them concludes 
that zero surface charged particles have lower cellular uptake when compared to charged 
particles [117-119]. This may be explained by the negatively charged cell membrane [106].  
In what concerns hydrophilicity, performed studies using polyethylene glycol (PEG), 
revealed that as hydrophilicity increases in particles’ surface, the uptake of these particles 
decreases [111, 112, 113].  
Besides the aforementioned factors, functional groups are also an important parameter that 
influences the particles internalization. These functional groups will modify the surface charge 
or hydrophilicity. Therefore, the same conclusions as the ones above can be taken accordingly 
to the specificities of the used functional groups. For a more extensive review about the 
mentioned parameters, [106] can be consulted. 
1.3.3. Nanofibrous Drug Delivery Systems 
Biomimetic nanostructures, that allow the production of synthetic analogs of different 
nano-components of the human body (with a special attention to the extracellular matrix 
(ECM)), have become of major importance in the study of cell biology, in regenerative medicine 
and medical device design [120]. From the whole set of nanostructures, nanofibers have 
deserved particular attention, as they can mimic the filamentary ECM or form a fibrous scaffold 
with encapsulated drugs. Moreover, they have reduced potential health hazards that are 
associated with discontinuous use of nanomaterials and nanoparticles [120]. The conventional 
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mechanical fiber spinning, the melt blowing or the island-in-the-sea methods are some of the 
described methodologies to produce fibrous structures. However, along with being very 
expensive methods, they cannot produce fibers with nano-diameters. One technique that can 
both combine the large scale fabrication of nanofibers and simplicity of the process, is 
electrospinning [120]. 
1.3.3.1. Electrospinning Process and Therapeutic Applications 
Electrospinning is emerging in the biomedical field, as a technique capable of fabricating 
fibers with nanometer range diameters, yielding very high surface areas, controlled porous 
architecture, ease of functionalization for different purposes, a 3D microenvironment and the 
possibility of encapsulating drugs in the nanofibers [120, 121]. It is briefly described as a type 
of fiber forming process by means of electrostatic forces that control the production procedure 
[122]. These forces exist to substitute the conventional mechanical forces that are 
conventionally used to produce a jet [120, 122]. Therefore, by using electrostatic energy, 
electrospinning’s basic principle is that strong electrical forces can overcome the surface 
tension ones in the polymer liquid [120, 123], allowing the formation of a jet and, 
consequently, by solvent evaoporation, of polymeric fibers. In order to perform the 
electrospinning procedure, some elements are required, including a polymer source, a high 
voltage supply and a collector, which can be either grounded or supplied with a negative 
charge to further attract the solution [123]. Figure 3 represents a schematic illustration for the 
electrospinning process. 
Depending on the desired application, several polymers can be used to produce nanofibers, 
from synthetic to natural polymers as well as from copolymer and polymer mixtures to 
homopolymers [124]. However, it is considered that in a general manner, polymeric solutions 
must have the following features: a surface tension low enough to be overcome by the 
electrical field; a charge density high enough to allow the surface tension to be overcome; a 
viscosity high enough to ensure sufficient chain entanglement to prevent the jet from 
collapsing into droplets before the solvent is evaporated [125]. 
Electrospinning technique has been widely applied in tissue engineering applications, with 
special attention to cardiovascular, neural, musculoskeletal and stem cell engineering [120]. In 
fact, the large surface areas associated with nanofibers, as well as the structural similarities 
between nanofibrous membranes and ECM, make nanofibers well suited to promote cell growth 
and the formation of three-dimensional cellular colonies [125]. Furthermore, nanofibers can 
also play an important role as being nanocarriers for drug delivery, as their dimensions and 
surface properties can be specifically tailored to adjust and control the release of active 
ingredients [125] as well as these carriers can be very malleable in order to be adapted to 
different applications. Moreover electrospun mats have the ability to overcome drug loading 
limitations seen with other drug delivery devices [126]. Considering specifically bone 
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regeneration, nanofibrous matrices present several advantages. As electrospun nanofibers can 
mimic the topographic features of the ECM, they provide a large surface for cellular 
interactions in their fiber network, therefore functioning as both structural cell support as well 
as reservoir for controlled drug or growth factors release [127]. Moreover, nanofibers are able 
to fill large bone defects as well as they possess porosity [127] in proportions that may improve 
bone ingrowth in vivo [128]. Therefore, several studies have been applied to bone using 
electrospun nanofibers. These studies are in majority associated with filling defects in bone by 
using biodegradable materials that aim to promote cell adhesion. Other approaches aim to 
combine nanofibers with compounds that promote bone regeneration, turning the nanofibers 
into drug delivery systems. Several studies have been performed with different polymers in 
order to study the potential of nanofibrous structures as drug delivery systems to bone. Among 
others, PCL is one of the most extensively used polymers [129-133], as its low degradation rate 
makes this polymer a great candidate for long-term implants for drug release. Piskin et al [134] 
have combined simvastatin with PCL, obtaining good results in enhancing bone defect healing. 
Yoshimoto et al [135] have also studied the potential of microporous PCL scaffolds, made by 
electrospun fibers, combined with osteogenic factors. Their results have shown that, after four 
weeks, the constructs were covered with cellular multilayers, showing the great usability of 
these PCL scaffolds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic view of the electrospinning process. (a) high voltage power supply; (b) syringe 
pump; (c) syringe containing the polymeric source; (d) collector. Scheme adapted from [122, 125]. 
Therefore, considering all the aforementioned mentioned characteristics, electrospun 
nanofibers constitute a powerful new source to be explored in the design of solutions for bone 
regeneration, both by acting as a mechanical support, as well as a delivery system of drugs that 
may aid in bone formation. 
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CHAPTER 2 
 
Aim of the Thesis 
 
 
 
The NPY Y1 receptor has arisen as a potential regulator in the local control of bone 
turnover. In vitro studies using BIBP3226, a potent Y1 receptor selective antagonist, showed 
that blocking this receptor has a positive impact in bone mass, thus providing good perspectives 
for BIBP3226 use as a pharmacological tool for bone regeneration. Still, considering the 
ubiquitous expression of Y1 receptor in the body and the antagonist intrinsic characteristics 
(such as its low bioavailability and short half-life), a particle delivery system, that protects the 
antagonist from clearance and degradation and enables its controlled release to the bone, 
offers much greater potential as compared to the drug administration alone. Moreover, as 
nanofibers can both offer support (as a scaffold) for bone regeneration as well as they can work 
as a delivery system, these nanostructures can also bring advantages in drug delivery for bone 
regeneration. 
Considering the fact that Y1 receptor is located at the cell membrane, a key feature of such 
system would be drug release at the extracellular space. Therefore, in this work we aim to 
optimize both a particle and a nanofiber-based systems for the local delivery of BIBP3226 to the 
extracellular space of bone defects. The specific aims are: 
1. Evaluation of the effect of size on particle internalization in bone marrow derived 
cells. In order to do this, particles with sizes ranging from 100 nm to 200 nm, from 
400 nm to 500 nm and from 800 nm to 1000 nm must be prepared.  
2. Determination of the cytotoxicity of the differently sized Particles; 
3. Design of a nanofibrous delivery system. 
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CHAPTER 3 
 
Materials and Methods 
 
 
 
3.1. Preparation and Characterization of the Polymeric 
Particles 
The particles preparation was performed using three different polymers: PCL (Mn of 80,000 
g/mol), which was a kind offer from Diana Leite (INEB) [93], and PLGA with a monomer 
composition of 55:45 (Mn from 30,000 to 60,000 g/mol) (Sigma-Aldrich, Portugal). Particles 
were prepared by the Salting-out method, with exception of PLGA that was both used to 
prepare particles by Salting-out and nanoprecipitation methods. After evaluation of sizes and 
stability, the following work after particles preparation and characterization was only 
performed with PLGA. 
 
3.1.1. Particles Preparation 
Particles were prepared using both the Nanoprecipitation and the Salting-out methods 
following protocols adapted from Cheng et al. and Chang et al. [136, 137] and Zhang et al. 
[138], respectively. 
The Salting-out method comprises two steps. Briefly, in a first step, a solution of 
Tetrahydrofuran (THF) (Sigma-Aldrich, Germany) containing 2.00% (wt/vol) of polymer was 
emulsified into an aqueous solution containing 60.0% (wt/vol) of Magnesium Chloride 
Hexahydrate (MgCl2.6H2O) (Amresco, USA) and variable concentrations of Poly(vinyl alcohol) 
(PVA) (Sigma-Aldrich, USA), ranging from 0% to 8.00% (wt/vol). This emulsification was 
performed under mechanical stirring at a speed ranging from 11400 to 29900 rpm (Homogenizer 
VWR, VDI 12) for 40 seconds. Secondly, after obtaining the oil-in-water emulsion, either an 
aqueous solution of 0.500% (wt/vol) of PVA (Sigma-Aldrich, USA) or pure water (Synergy 
Ultrapure Water Systems, Millipore®) was quickly added and stirred for 30 seconds. In order to 
evaluate the impact of the solutions’ volume in particle formation and loading, variable 
amounts of solutions were used, always maintaining the volumes ratio (Table III). Where 
nothing is referred in contraire, the volumes used in the Salting-out procedure were the ones 
referred in Table III as being the Condition 3.   
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Table III. Volumes of solutions used in the Salting-out method. 
 
Condition 
 
Polymeric Solution 
in THF (mL) 
 
MgCl2.6H2O + PVA 
Solution (mL) 
 
PVA solution or pure 
water (mL) 
 
1 
 
1.00 
 
1.82 
 
1.82 
 
2 
 
2.00 
 
3.63 
 
3.63 
 
3 
 
3.00 
 
5.45 
 
5.45 
 
Regarding the nanoprecipitation method, it comprises only one step. Firstly 10 mg of 
polymer were dissolved in 1.00 mL of Acetonitrile (ACN) (Merck Millipore) or N,N-
Dimethylformamide (DMF) (Sigma-Aldrich) and added to 10.0 mL of Milli-Q water (Synergy 
Ultrapure Water Systems, Millipore®), by means of a 25G needle. This addition was performed 
under magnetic stirring at a moderate velocity. 
Particles loaded with Dexamethasone (Sigma-Aldrich) or Coumarin-6 (Sigma-Aldrich) were 
prepared accordingly to the previous specifications, except that the polymer was dissolved in a 
solution of THF containing 1.00%(wt/vol) of Dexamethasone or 0.0300%(wt/vol) of Coumarin-6. 
 
3.1.2. Particles Purification 
The particles solutions obtained from the Salting-out method were purified by 
centrifugation (Eppendorf Centrifuge 5417R) for 30 minutes, at 20ºC. Each polymer had a 
respective centrifuge force, which are present in the Table IV. After centrifugation the 
supernatant was removed and the particles were redispersed in an aqueous solution containing 
0.125% (wt/vol) of PVA or pure water. The procedure of centrifugation and redispersion of 
particles was repeated twice. 
 
Table IV. Centrifuge forces used in the purification of the prepared particles with different polymers: 
PCL, mPEG-PTMC and PLGA. 
 
Polymer 
 
Centrifuge Force (× 𝟏𝟎2 g) 
 
PCL 
 
78 
 
mPEG-PTMC 
 
208 
 
PLGA 
 
52 
 
In what concerns the nanoprecipitation method, the particles were purified by 
centrifugation or filtration. In the centrifugation option, the method was similar to the one 
described above for the Salting-out method. However, in this case, the centrifuge force 
corresponded to 3200 g and the centrifugation time to 20 minutes. The particles were then 
redispersed in an aqueous solution containing 0.125% (wt/vol) of PVA. The whole procedure was 
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also repeated twice. Regarding the filtration, the particles solution was filtered using a 1 mL 
syringe and a 70 µm filter, in a single step. 
 
3.1.3. Particles Freeze-Drying 
After the last step of purification, particles were redispersed in a solution containing a ratio 
of 2:1 (sugar:particle mass ratio) of sucrose. This step aimed to protect the particles against 
the destabilization induced by the freeze-drying. After this, the particles solutions were frozen 
at -80ºC and freeze-dried (Bentch top pro) under vacuum for 2 to 3 days. 
 
3.1.4. Particles Characterization 
Particles’ size and size distribution, which is characterized by the polydispersity index 
(PDI), were determined by dynamic light scattering (DLS) (Zetasizer Nano, Malvern Instruments) 
at 25ºC at an angle of 173º. Regarding PDI, it is a dimensionless number that lies between 0 and 
1 and indicates the scatter of the size distribution, being 0 the indication of a monodisperse 
particle suspension. The particles size and PDI were determined accordingly to the ISO13321 
(1996) and ISO22412 (2008). 
 
3.1.5. Loading Efficiency of Dexamethasone in the Particles 
After Freeze-Drying, Dexamethasone-loaded particles were dissolved into deuterated 
Dimethyl Sulfoxide (DMSO) (Merck Millipore). Dexamethasone loading of the particles was 
determined by Proton Nuclear Magnetic Resonance Spectroscopy (1H-NMR) (Bruker Avance III 
400 MHz). In order to obtain the results, the integral of the Dexamethasone peaks (1H, δ=7.3-
7.28 ppm; 1H, δ=6.23-6.20 ppm; both peaks correspond to –CH groups in the Dexamethasone 
structure) and the integral of the PLA peak (3H, δ=4.8-4.9 ppm; the peak corresponds to a –CH3 
group in the PLA structure) were both calculated. By applying Equation 1 it was possible to 
determine the maximum possible loading (% wt), while Equation 2 (where Sum of the integrals 
of the drug peaks corresponds to the values obtained by the integration of the above 
mentioned peaks for the Dexamethasone and Integral of the polymer peak corresponds to the 
the values obtained by the integration of the values obtained for the above mentioned peak for 
the PLA) allowed the calculation of the theoretical loading (% wt) during the procedure. 
  
Theoretical Loading (% wt) =
Drug mass
Polymer mass
 × 100 
(Equation 1) 
 
 
Achieved Loading (% wt) =  
(Sum of the integrals of the drug peaks) 2⁄
(𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑙 𝑜𝑓 𝑡ℎ𝑒 𝑃𝑜𝑙𝑦𝑚𝑒𝑟 𝑝𝑒𝑎𝑘) 3⁄
 × 55 
(Equation 2)
Therefore, loading efficiency (%) was calculated by the results from the aforementioned 
Equations. 
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3.2. Biocompatibility and Internalization assays 
 
3.2.1. Cell Culture 
The internalization studies were performed in mice Bone Marrow Cells derived Osteoclast 
Lineage ( which will be abbreviated as BMC). Cells were collected from the femurs and tibias of 
a C57BL/6 mouse with 12 weeks. Cells were left in culture in Minimum Essential Medium Eagle – 
Alpha Modification (α-MEM) (Gibco - Life Technologies) supplemented with 10.0% Fetal Bovine 
Serum (FBS) (Gibco - Life Technologies), 1.00% Penicillin Streptomycin (P/S) (Gibco- Invitrogen) 
and 30 ng/ml of M-CSF (PeproTech EC). After 3 days of incubation at 37ºC in fully humidified 
atmosphere of 5% CO2, the attached cells were harvested with 0.05 M EDTA (Sigma-Aldrich) at a 
pH 8, seeded in µ-Slide 8 Well Plates (Ibidi) at a density of 1x105 cells/well and cultured in the 
above described medium supplemented with 100 ng/ml of RANKL (PeproTech EC). The addition 
of these cytokines aimed the differentiation of the BMC into osteoclasts. Culture medium was 
replaced at every 3-4 days for up to 7 days.  
Following 3 and 7 days of differentiation, cells were incubated with Coumarin-6 loaded 
particles of three different sizes at a concentration of 0.0400% (wt/vol) and 10.0% Resazurin (as 
mentioned in more detail in the section 3.2.2). After 3 hours of incubation at 37ºC and 5% CO2, 
Resazurin results were assessed and Live/Dead assay and F-actin staining were performed. 
Controls using cells incubated in the absence of particles and in the presence of 0.000600% 
(wt/vol) of Coumarin-6 were performed.  
 
3.2.2. Resazurin Assay 
Cell metabolic activity was assessed by the Resazurin assay. Therefore, at the time of the 
addition of the particles, 10.0% (v/v) of Resazurin (Sigma-Aldrich) was added to each well and 
incubated at 37ºC and 5% of CO2. Following, 150 µL of the supernatant were transferred, in 
duplicate, into a black 96-well plate and the fluorescence (λex = 530 nm and λem = 590 nm) was 
measured using a microplate Fluorometer (Spectra Max GeminiXS Molecular Devices). Blanks for 
fluorescence emission subtraction were performed with cell culture medium, Coumarin-6 and 
particles of each size.  
 
3.2.3. Live/Dead Assay 
The percentage of viable cells was calculated by the Live/Dead assay. After the 3 hours of 
incubation with the particles, cells were rinsed twice with Phosphate Buffered Saline (PBS), and 
incubated with Calcein AM (Molecular Probes – Invitrogen) (1:1000 in warmed PBS 1x) for 20 
minutes, at 37ºC, 5% of CO2. Following, cells were rinsed twice with PBS and incubated with 
Propidium Iodide (Sigma-Aldrich) (1:500 in warmed PBS 1x) for 5 minutes, at 37ºC, 5% CO2. 
Results were assessed with an inverted microscope Leica DMIRE2 (Leica Microsystems, 
Germany), using the LCS 2.61 (Leica Microsystems, Germany) software. 
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3.2.4. Immunocytochemistry for F-Actin assay 
In order to evaluate cell morphology, an immunocytochemistry for F-Actin assay was 
performed. After the 3 hours of incubation with the particles, cells were washed twice with 
PBS, fixed with 4.00% Paraformaldehyde (PFA) (Sigma-Aldrich) for 10 minutes at 4ºC and 
permeabilized in ice-cold 0.250% (v/v) Triton X-100 (Amersham Biosciences-VWR) (in PBS 1x) 
for 5 minutes. In order to block non-specific binding, cells were incubated with 1.00% (wt/vol) 
Bovine Serum Albumin (BSA) (in PBS 1x) for 1 hour. Cells were then stained with Alexa Fluor 594 
Phalloidin (Life Technologies) (1:100 in PBS 1x) at room temperature (RT) for 20 minutes in the 
dark. After rinsing the cells twice with PBS, they were incubated for 5 min at RT with 4′,6-
Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich) (1:1000 in PBS 1x). Samples 
were analyzed by Inverted Fluorescence Microscopy (Axiovert 200M (Zeiss)) using the Axiovert 
software. 
 
3.3. Electrospun Fibers 
Nanofibers were produced following a protocol adapted from Liliana Pires et al. [139]. In 
order to test which formulation was better, PCL was used as the polymer and Dichloromethane 
(DCM) (VWR Chemicals) and N,N-Dimethylformamide (DMF) (Sigma-Aldrich) were the solvents. 
The previously optimized conditions to perform the experiment were the following: flow rate of 
1 mL/hour using a syringe pump (Ugo Basile, Italy); an electric field (Gamma High Voltage 
source, Ormond Beach, FL, USA) of 1 kV/cm, applied between the tip of the syringe (inner 
diameter of 0.8 mm) and a flat copper plate (15x15 cm) separated by 14 cm. To achieve this, 
different formulations of the polymeric solution were used: three different solutions containing 
a DCM and DMF volume ratio of 1:0, were prepared with a concentration of 10.0%, 13.0% and 
15.0% (wt/vol) of PCL; a solution containing a volume ratio of 4:1 was prepared with a 
concentration of 10.0% (wt/vol) of PCL. All the solutions were tested and the fibers were 
collected in an aluminum foil for 1 up to 1.5 hours. Images from the produced results were 
analyzed in an Inverted Fluorescence Microscope Axiovert 200M (Zeiss) and Axiovert software. 
 
3.4. Statistical Analysis 
The statistical analyses were performed, where specified, using the IBM SPSS Statistics 20.0 
software. Shapiro-Wilk test was applied to assess the normality of the samples. One way ANOVA 
tests were performed in order to test the homogeneity of the samples, with following Post Hoc 
(for parametric samples) or Kruskal Wallis followed by Mann Whitney (for non-parametric 
samples).  Results were considered significantly different for samples with p≤0.05. 
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CHAPTER 4 
 
Results and Discussion 
 
 
 
4.1. Optimization of the Particles Preparation Procedure 
The polymeric solution used to prepare particles will strongly affect the structure, 
properties and application of the particles [89]. As it is intended the delivery of a hydrophobic 
drug, the initial choice of polymers was centered in hydrophobic and amphiphilic compounds: 
PCL, PLGA and mPEG-PTMC, available in our laboratory. However, Zhang et al. [138] reported 
that in the case of mPEG-PTMC the particles size does not vary significantly in spite of large 
variations in the procedure parameters. This property is associated with the self-stabilizing 
properties of the mPEG segment. Considering that one of the aims of the present work was to 
prepare differently sized particles, this polymer was not considered for the study. Therefore, 
only PCL and PLGA were initially assessed in what concerns their performance during the 
preparation and purification procedures and, consequently, one of them was chosen has being 
the more suitable for performing the following experiments. 
In addition to the delivery of an hydrophobic drug, it is intended that the delivery occurs in 
the extracellular space, as the Y1 receptor is transmembranar. Although some studies refer 
desirable characteristics in particles for an extracellular delivery, there is not a consensus in 
which are the most suitable ones. As reviewed by Kettler et al. [106] there are some studies 
referring that non-phagocytic cells will easily uptake smaller particles, usually with a size 
bellow 200 nm, by endocytosis, while phagocytic cells will uptake the larger ones, usually with 
a size comprised between 500 nm and 1000 nm, by phagocytosis. Therefore, taking in 
consideration a heterogeneous cellular population such as the bone marrow, where there is a 
presence of both phagocytic and non-phagocytic cells, a size between 200 nm and 500 nm 
would possibly be the most suitable choice. However, to the best of the author’s knowledge, 
none of these studies was performed in bone cells. Therefore, the Salting-out and 
Nanoprecipitation methods were optimized in order to prepare particles with dimensions 
ranging from 100 nm to 1 µm: a first group with particles with a size from 100 nm to 200 nm, a 
second one with sizes ranging from 400 nm to 500 nm and a last one with particles having a 
diameter comprised between 800 nm and 1000 nm. By obtaining these three differently sized 
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groups, it would be possible to assess the behavior of the cells when incubated with the 
particles and verify if the hypothesis that a size between 200 and 500 nm is confirmed. 
In an initial phase, Salting-out was the chosen method to prepare particles. The Salting-out 
method is included on the methods for the preparation of particles that comprise two main 
steps. The first step corresponds to the preparation of an oil in water emulsion. In order for this 
to happen, the polymeric solution is emulsified into an aqueous solution containing high 
concentrations of a salt (in this case, Magnesium Chloride) with strong salting-out effect. The 
polymer is, at this stage, dissolved in the droplets of the emulsion. The second step of the 
method corresponds to the particles formation, which occurs by the polymer precipitation. This 
precipitation is induced by diluting the emulsion with a large excess of water. This dilution will 
lead to a drop in salt concentration in the continuous phase of the emulsion, inducing the 
polymer solvent to migrate out of the emulsion droplets and, consequently, forming the 
particles. The whole procedure is usually aided by mechanical processes (in this case, by 
homogenization). In order to improve the stability of the final polymeric particles, a stabilizer 
(in this system, it was used PVA) can also be used [91]. With the aim of obtaining differently 
sized particles, some parameters on the Salting-out method were varied. With effect, the 
parameters on this procedure can be easily modified in order to obtain differently sized 
particles: by augmenting the polymer’s concentration and polymer molecular weight, it is 
possible to obtain larger particles. A reverse situation occurs with the stirring rate and 
stabilizer concentration, as the increase of these parameters leads to smaller particles. The 
type of solvent, surfactant and cryoprotectant used for Freeze-Drying are also influencing 
parameters on the final particles’ size results [140]. Therefore, taking into consideration all 
these factors, variations in both the stirring rate and the stabilizer concentration were 
performed in order to modulate the particles size and polydispersity index (PDI), which 
corresponds to an dimensionless number, between 0 and 1, indicating the scatter of the size 
distribution, being 0 the indication of a monodisperse particle suspension. Both size and PDI 
were obtained by measurements performed in Zeta-Sizer. However, as it will be discussed 
hereinafter, as it was not possible to obtain particles with a size below 250 nm by this method, 
another method was tested: the Nanoprecipitation.  
In what concerns Nanoprecipitation, it is constituted by only one step and it has three basic 
ingredients: the polymer, the polymer solvent (in this case, acetonitrile and N,N-
dimethylformamide) and the non-solvent (in this experience it was chosen water) of the 
polymer. In order to produce the particles, the polymeric solution is added to the non-solvent. 
The particles form instantaneously, as the polymer solution rapidly diffuse in the non-solvent 
solution [91] and the polymer chains aggregate forming particles [141]. In what concerns this 
procedure, the obtained particles can have different sizes by varying the polymer’s 
concentration and molecular weight, the solvent’s and surfactant’s nature and the phase 
injection. The presence of additives and active component entrapment may also influence the 
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obtained sizes [140]. In the performed experiments, only the solvent’s type was varied in the 
Nanoprecipitation procedure. However, as the particles prepared by this procedure were too 
small, it was also studied the influence of the purification procedure on the obtained particles, 
as centrifugation could be too powerful for such small particles and, consequently, lead to their 
aggregation.  
In addition to the achievement of differently sized particles, it was performed a parallel 
study in which the volumes used in the Salting-out method were varied in order to evaluate the 
influence of this variation in both particles’ size and drug loading. Results are shown 
hereinafter. 
 
4.1.1. Polymer Effect 
Both PCL and PLGA particles were prepared equally by the Salting-out method: 5.00% 
(wt/vol) of PVA in the first step and 0.500% (wt/vol) of PVA in the second one, followed by 
purification by centrifugation with 0.125% (wt/vol) of PVA.  
During the procedure of particles preparation, the two polymers had a similar behavior, as 
they equally originated a suspension of particles, which was noticeable for the suspensions’ 
milky appearance. Moreover, the characterization of the particles regarding their size and PDI 
(Figure 4) reveals the presence of particles with a narrow distribution of sizes, as the PDI is low 
for all the prepared particles. 
  
 
 
 
 
 
 
 
 
 
 
Figure 4. Mean Size of the particles prepared with PCL and PLGA. The particles were prepared by the 
Salting-out method, comprising solutions with 5.00% (wt/vol) of PVA in the first step and 0.500% of PVA in 
the second one. The purification of these particles was performed with a solution of 0.125% (wt/vol) of 
PVA. The homogenization velocity was 2990x101 rpm for all the different polymeric particles. The size and 
PDI from the particles, both obtained by DLS, were measured right after purification. Results are 
presented as Average ± Standard Deviation (n=3, i.e., for each polymer it was prepared one batch and for 
each batch 3 measurements were performed). At the top of each bar is represented the mean PDI values 
for each group. * Particles’ size was significantly different between the signaled conditions, considering p 
≤ 0.05. 
* 
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It is noticeable that the particles’ size differs from one polymer to another, which is 
associated with polymers molecular weight: the higher the molecular weight, the larger the 
particles are [140, 142]. This is in agreement to the obtained results as PLGA has a lower 
molecular weight than PCL. The hypothesis behind this assumption is that polymers with higher 
molecular weight will lead to a more viscous polymeric solution [142], thereby affecting the 
stirring process. In turn, this will conduce to larger emulsion droplets, resulting in larger 
particles. After preparation, particles were purified by centrifugation in order to remove 
impurities and excess reagents.  
If in one hand, the two polymers had a similar performance during the preparation phase, 
the same has not happened during the purification procedure. It was expected that, after 
centrifugation, the particles in suspension formed a pellet, which allowed to discard the 
supernatant followed by resuspension of the particles in 0.125% (wt/vol) of PVA in water and 
new centrifugation. However, for PCL, this did not occur and the polymeric particles formed a 
film at the liquid surface, leading to a loss of particles mass, as the task of discarding the 
supernatant was hampered. It is hypothesized that PCL has degraded with the time, therefore 
leading to this problem.  
In what concerns particles formed with PLGA, they formed a pellet, as well as they were 
easily redispersed after centrifugation. Therefore, this polymer revealed a more suitable 
behavior for the intended following work, being, from the three initially proposed polymers, 
the selected one to proceed this project. 
 
4.1.2. Effect of Volumes’ Variations on both Particles’ Size 
and Drug Loading Efficiency 
The Salting-out method was optimized by Zhang et al. [138] for a volume of polymeric 
solution of 5.5 mL. This protocol was adapted by Diana Leite [93] for a volume of polymeric 
solution of 3 mL, adjusting all the other solutions’ volumes so as to maintain the same ratio 
between them. However, as BIBP3226 is a very expensive reagent, in order to spend less 
reagents and drug per batch, it was evaluated if the variance of the volumes would affect both 
the particles’ size and drug loading efficiency. Therefore, PLGA particles were prepared by the 
Salting-out method, accordingly to the optimization performed by Diana Leite [93]: 2.00% 
(wt/vol) of PVA in the first step and 0.500% (wt/vol) of PVA in the second one, followed by 
purification by centrifugation with 0.125% (wt/vol) of PVA; the polymer concentration 
corresponded to 2.00% (wt/vol) and the drug concentration to 1.00% (wt/vol). Three different 
trials were performed as explained in the Section 3.1.1 (Condition 1 was prepared with the 
lowest volumes, Condition 2 correspond to the particles prepared with intermediate volumes 
and the largest volumes were addressed in Condition 3).  
The obtained results (Figure 5) show that, although not statistically different, Condition 1 
had a larger size when compared to conditions 2 and 3. The volumes used in Condition 1 did not 
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cover completely the homogenizer tip, which may have influenced the homogenization 
efficiency and led to the obtained results. However, as results were not statistically different, 
this circumstance did not influenced significantly the particles’ size. 
 
Figure 5. Mean size of the particles prepared with different volumes. Volume from Condition 1 
corresponds to the particles prepared with 1 mL of polymeric solution, Volume from Condition 2 regards 
the particles prepared with 2 mL of polymeric solution and the Volume from Condition 3 comprises the 
particles prepared with 3 mL of polymeric solution. All the volumes for the used solutions in the 
preparation procedure are specified in the Table III, Section 3.1.1. The particles were prepared by the 
Salting-out method, comprising solutions with 1.00% (wt/vol) of Dexamethasone, 2.00% (wt/vol) of PVA in 
the first step and 0.500% of PVA in the second one. Purification was performed with a solution of 0.125% 
(wt/vol) of PVA. The homogenization velocity was 2990x101 rpm. The size and PDI from the particles, both 
obtained by DLS, were measured after purification. Results are presented as Average ± Standard Deviation 
(n=3, i.e., for each batch 3 measurements were performed). At the top of each bar is represented the 
mean PDI values for each group.  
Drug entrapment efficiency is usually associated to a set of parameters related with the 
particles preparation method. By increasing the polymer concentration, the organic phase 
viscosity is increased, leading to a higher diffusional resistance to drug molecules from the 
organic phase to the aqueous phase and, consequently, to the entrapment of more drug in the 
polymer particles. On the other hand, by increasing the aqueous phase volume, larger particles, 
which are reported as having higher drug contents, are formed. By increasing the initial drug 
content, the drug incorporation process operates until its maximum efficiency, determined by 
the drug miscibility in the polymer at the given conditions, and then it reaches a plateau. 
Therefore, drug and polymer’s characteristics must be studied in order to better understand 
their interaction. Finally, by decreasing the stabilizer concentration, the drug content in the 
particles increases, which is mainly associated with the augmentation in the particles size 
[143]. In the case of the purification phase, other parameters can be modified such as 
decreasing the volume of the used purifying aqueous solution. By decreasing this volume, the 
solutions’ saturation will be reached more quickly, forcing the drug to be adsorbed at the 
particles surface. With this in mind, drug loading efficiency was evaluated by 1H-NMR for the 3 
conditions prepared with different volumes (Table V).  
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Table V. Drug loading efficiency of the prepared Dexamethasone loaded PLGA particles with different 
volumes. Condition 1 corresponds to the particles prepared with 1 mL of polymeric solution, Condition 2 
regards the particles prepared with 2 mL of polymeric solution and the Condition 3 comprises the particles 
prepared with 3 mL of polymeric solution. All the volumes for the other used solutions in the preparation 
procedure are specified in the Table III, Section 3.1.1.. The particles were prepared by the Salting-out 
method, comprising solutions with 1.00% (wt/vol) of Dexamethasone, 2.00% (wt/vol) of PVA in the first 
step and 0.500% of PVA in the second one. Purification was performed with a solution of 0.125% (wt/vol) 
of PVA. The homogenization velocity was 2990x101 rpm. Results were obtained, after Freeze-Drying, by 
1H-NMR and using Equations 1 and 2, being the Loading Efficiency calculated by considering the 
theoretical loading as being 100% (n=1). 
Condition 
Loading (% wt.) 
 
Loading Efficiency 
(%) Theoretical Obtained 
1 
50.00 
5.45 10.9 
2 1.18 2.36 
3 1.43 2.86 
 
As it is observable, Condition 1 has the highest drug loading efficiency. This may be 
associated to the larger particles’ size obtained for this condition (although sizes were not 
statistically different, Condition 1 had a larger size). However, the result here obtained for 
Condition 1 is similar to the one obtained by Diana Leite [93], who has prepared 
Dexamethasone loaded PLGA particles, using a volume for the polymeric solution of 3 mL (i.e., 
used the same conditions as the ones defined in this project for condition 3). Therefore, these 
results suggest that the differences in volume may not affect the loading and the reason 
beyond the differences here obtained are associated with problems occurred during the 
preparation procedure. For confirmation, more independent batches should be further 
prepared and characterized in regards to their size and loading efficiency. 
 
4.1.3. Particles’ Size Optimization 
As previously referred, it was initially stipulated that sizes should be optimized for three 
different ranges of particles’ sizes, between 100 nm and 1 µm: Small Particles should have a 
size between 100 nm and 200 nm, Medium Particles should range between 400 nm and 500 nm 
and Large Particles should vary between 800 nm and 1000 nm. In order to obtain these 
particles, the Salting-out method was initially chosen to prepare the particles. Therefore, 
stirring rate and surfactant concentration were modified during the procedure with the 
intention of modifying the particles size.  
Accordingly to different studies [138, 144, 145], an increase in the stirring rate results in a 
decrease of the particles’ size. This result is related to the formed droplets during the 
emulsification process [138]: the higher the stirring rate, the lower the droplets size. In fact, 
this droplets size is determined by the balance between the relative kinetics of the break-up 
and coalescence of the droplets, which are phenomena occurring simultaneously during 
emulsification and both influenced by the stirring rate [144].  
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Concerning the surfactant, studies [141, 146-148] have demonstrated that by augmenting 
the concentration of PVA, particles size decreases. PVA is a copolymer that usually acts as a 
stabilizer during the procedure of emulsification in different particles’ preparation methods. 
This compound has influence both in the formed emulsification droplets and in the bulk 
solution: if in one hand the PVA can reduce interfacial tension, and induce mechanical and 
steric stabilization at the droplets’ interface, where polymer chains interact, on the other 
hand, the non-adsorbed PVA chains contained in the bulk solution will influence the continuous 
phase viscosity, controlling the disruption kinetics of the droplets and promoting hydrodynamic 
stabilization. By lowering the interfacial tension at the droplets’ interface, PVA allows a 
significant reduction in the energy required during emulsification. This tension reduction is 
mainly associated to PVA’s amphiphilic character (the acetate groups constituted the 
hydrophobic part, while the hydroxyl ones correspond to the hydrophilic one) that allows PVA 
to be adsorbed and oriented at liquid-liquid interfaces, leading to the formation of a disperse 
system. Besides this stabilization, PVA can also cover completely the droplets, forming a firm 
anchoring at the interface and leading to the formation of a thick film. For this reason, it is 
possible for the polymer chains to have an optimal conformation into the external phase. 
Finally, the steric benefits arise from the short-range entropic repulsion between droplets, 
which is a result from the stabilization performed by PVA at the droplets surface [141].  
Moreover, PVA plays an important role during the purification phase. Galindo-Rodriguez et 
al. [141] have studied the purification of particles by centrifugation and filtration, in order to 
assess the presence of residual PVA at the particles’ surface. Their results show that, in both 
purification methods, there is a resistance of PVA to complete removal, suggesting that it is 
physically incorporated onto the particles surface. If on one side this may be advantageous for 
particles redispersion in water, as PVA hampers the particles’ aggregation [141, 146], on the 
other hand it can alter the particles characteristics concerning specially their hydrophobicity 
and, therefore, their interaction with cells and cellular uptake [147]. Therefore, an equilibrium 
on PVA’s concentration must be implemented. 
Therefore, by increasing both PVA concentration and stirring rate, it was predictable to 
obtain smaller particles and vice versa. As a first attempt, these parameters were modified and 
the obtained results (Table VI) were in accordance with the expected. Yet, the obtained sizes 
in this first attempt were yet outside the predefined initial ranges. Therefore, further 
optimizations were performed (Table VII). However, as the presence of an extra compound in 
the mixture can alter the viscosity of the organic phase and, consequently, alter the stirring 
process, leading to differences in the final obtained sizes [149], this time particles were loaded 
with Coumarin-6. Coumarin-6 is a fluorescent marker, that, when entrapped inside the 
particles, confers a green color to them. By producing Coumarin-6 loaded particles, it is 
possible to track the particles destination when in contact with cells.  
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Table VI. PLGA particles size and preparation conditions. All PLGA particles were unloaded and were 
prepared by the Salting-out method, using the parameters specified in the Table. PVA concentrations used 
in the different phases of the procedure are here specified, where 1st step corresponds to the formation of 
the oil-in-water emulsion and 2nd step refers to the diffusion of the solvent into the aqueous phase. The 
column referred as purification presents the percentage of PVA used to purify the particles. Mean size and 
PDI results are demonstrated in the Obtained Mean Size and PDI columns, respectively. This 
characterization was performed right after the particles purification (i.e., particles were not freeze dried) 
by measurements performed by DLS. Results are presented as Average ± Standard Deviation (n=3, i.e., for 
each condition it was prepared one batch and for each batch 3 measurements were performed).  
Experiment 
  
1st step 
(% of PVA 
in wt/vol) 
 
2nd step 
(% of PVA 
in wt/vol) 
Stirring 
Rate  
(× 𝟏𝟎1 rpm) 
Purification 
(% of PVA 
in wt/vol) 
Obtained 
Mean Size 
(nm) 
PDI 
A.I 5.00 0.500 2990 0.125 
 
355.0 ± 
2.2 
 
0.109 ± 
0.031 
A.II 2.00 0.500 2045 0.125 
 
715.2 ± 
99.1 
 
0.181 ± 
0.024 
A.III 0.50 0 1140 0.125 
 
2106.7 ± 
307.2 
 
0.431 ± 
0.344 
 
Table VII. PLGA particles size after the optimization of the parameters in the preparation procedure. 
All the PLGA particles were loaded with 0.0300 % (wt/vol) of Coumarin-6 and were prepared by the 
Salting-out method, using the parameters specified in the Table. PVA concentrations used in the different 
phases of the procedure are here specified, where 1st step corresponds to the formation of the oil-in-
water emulsion and 2nd step refers to the diffusion of the solvent into the aqueous phase. The column 
referred as purification presents the percentage of PVA used to purify the particles. Mean size and PDI 
results are demonstrated in the Obtained Mean Size and PDI columns, respectively. This characterization 
was performed right after the particles preparation (i.e., particles were not freeze dried) by 
measurements performed by DLS. Table is organized in an ascending order of obtained mean size. Results 
are presented as Average ± Standard Deviation (n=3, i.e., for each condition it was prepared one batch 
and for each batch 3 measurements were performed). 
Experiment 
  
1st step 
(% of PVA 
in wt/vol) 
 
2nd step 
(% of PVA 
in wt/vol) 
Stirring 
Rate  
(× 𝟏𝟎1 rpm) 
Purification 
(% of PVA 
in wt/vol) 
Obtained 
Mean Size 
(nm) 
PDI 
B.I 8.00 0.500 2990 0.125 
 
265.4 ± 
1.9 
 
0.091 ± 
0.027 
B.II 2.00 0.500 2990 0.125 
 
409.2 ± 
0.3 
 
0.159 ± 
0.014 
B.III 2.00 0 2045 0 
 
1013.2 ± 
40.4 
 
0.236 ± 
0.022 
B.IV 5.00 0.500 1445 0.125 
 
1041.0 ± 
105.9 
 
0.504 ± 
0.100 
B.V 2.00 0 1445 0 
 
1944.0 ± 
96.8 
 
0.273 ± 
0.087 
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Experiment B.II (409.2 ± 0.3 nm) was considered optimized for the achievement of the 
Medium Particles (which were defined as particles with a size within the range from 400 to 
nm). Although Experiment B.III (1013.2 ± 40.4 nm) is above the mentioned range for the Large 
Particles (from 800 to 1000 nm), taking into account the result and its standard deviation, it 
was considered optimized for the mentioned group. Following the same reasoning, Experiment 
B.IV (1041.0 ± 105.9 nm) could also be considered as optimized for the Large Particles group. 
However, when comparing PDI values from both Experiments, condition B.III presented a lower 
value. PDI, as previously referred, is associated to the scattering of the size distribution on a 
particle suspension: it varies from 0 to 1, meaning that as closer to 0, the narrower is the 
particles’ size distribution. Therefore, as PDI from Experiment B.IV (1041.0 ± 105.9 nm) was 
higher than the one obtained in Experiment B.III (1013.2 ± 40.4 nm), the latest’s parameters 
were chosen as being optimized in detriment of the ones from Experiment B.IV (1041.0 ± 105.9 
nm).  
As it is observable, any of the experimented conditions produced particles for the range 
from 100 to 200 nm, which corresponded to the chosen interval for the Small Particles group. 
The closest to the defined range is the result obtained in Experiment B.I (265.4 ± 1.9 nm), 
which was performed with the maximum stirring rate conceivable. Therefore, as it was not 
possible to increase more the stirring rate, it was performed an attempt of augmenting the 
concentration of PVA in the 1st step from 8.00% (wt/vol) to 10.0% (wt/vol). However, the 
solution at 8.00% (wt/vol) of PVA was already near its saturation point due to the high 
concentration of MgCl2.H2O hexahydratated. Consequently, the solutes had precipitated when 
the concentration of PVA was raised to 10.0% (wt/vol). Also, a high concentration of PVA is 
undesirable, as this compound is potentially carcinogenic and, as previously mentioned, it can 
alter the characteristics associated to particles’ cellular uptake [147, 150].  
Taking into account the aforementioned considerations, it was decided that other method 
should be studied for the development of the Small Particles (with a range between 100 and 
200 nm). Therefore, Nanoprecipitation method was studied as the method for obtaining the 
smaller particles, necessary for the internalization studies. In order to assess the most suitable 
parameters for the preparation of particles by nanoprecipitation, both the organic solvent and 
the purification method were varied, being the obtained results present in Figure 6. 
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Figure 6. Size of the particles prepared with the nanoprecipitation method. The preparation procedure 
was performed using N,N-Dimethylformamide (N,N-DMF) or Acetonitrile (ACN). The purification of the 
particles was performed either by centrifugation (Centr), with resuspension in a solution of 0.125% 
(wt/vol) of PVA, or Filtration (Filtr).  Both size and PDI values were obtained by measurements performed 
in DLS. Results are presented as Average ± Standard Deviation (n=3, i.e., for each condition it was 
prepared one batch and for each batch 3 measurements were performed). At the top of each bar is 
represented the mean PDI values for each group.. * Particles’ size was significantly different between the 
signaled conditions, considering p ≤ 0.05. 
Results show significant differences between particles prepared with different solvents and 
different purification methods, both before and after Freeze-Drying.  
Once the organic solvent is modified, the polymer-solvent and water-solvent interactions 
become different, inducing changes in the particles’ mean size [141]. Concerning the water-
solvent interactions, their influence on the particles’ mean size may be explained by the 
solubility of the solvents: the higher the solubility, the more efficient is the solvent diffusion 
into the aqueous phase. Furthermore, as the polymer is usually transported by the solvent, with 
higher solvent solubility the polymeric chains will be partitioned more efficiently in the 
external phase, forming aggregates and, consequently, particles [136, 141]. As DMF is a more 
water miscible solvent than ACN, it was expected that the mean size of the particles was lower 
in the samples prepared with DMF [136]. However, differences were only found between the 
samples prepared by DMF and purified by filtration, which presented a size of 591.3 ± 165.0 
nm, and the particles prepared with ACN and also purified by filtration, which presented a size 
of 361.0 ± 44.5 nm. Therefore, these results were not in agreement with the expected, 
meaning that other factors, such as the Freeze-Drying procedure or the purification method, 
may have introduced variables on the procedure, leading to these non-expected differences. 
Freeze-drying is one of the most suitable methods to stabilize and facilitate the handling of 
colloidal systems, which otherwise would be stored as suspensions [151]. It allows the removal 
of the particles solvent, resulting on dried particles. Although it is appropriate for preserving 
* 
* 
* * 
* 
* 
* 
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the original properties of particles, this procedure may bring some problems to the system, 
giving rise to the loss of integrity of the particles’ characteristics [91, 151]. For instance, ice 
crystallization may exert mechanical stress on particles leading to a destabilization. On the 
other hand, when the particles concentration is too high, freeze-drying may favor aggregation 
or irreversible coalescence of particles [91]. Therefore, it is important to find ways that may 
circumvent these problems, being one of the most used solutions the addition of 
cryoprotectants. Cryoprotectants can both improve the resistance of particles towards freezing 
and drying stresses, as well as the stability for long term storage. Sugars are the most popular 
cryoprotectants and, although their effect is mostly benefic, the ratio between 
cryoprotectant/particles is an important parameter, as above an optimal value, particles 
stability can be compromised [91]. Diana Leite [93] has optimized the procedure for a sugar : 
particles mass ratio of 2:1. Although it the referred study it was optimized the usage of glucose 
as a cryoprotectant for PLGA particles, sucrose is a disaccharide, therefore leading to the 
formation of a more complex glassy matrix around particles during the Freeze-Drying and, 
consequently, to a more efficient protection. For this reason, sucrose was used as a 
cryoprotectant for the particles at a ratio of 2:1, for the samples purified by centrifugation. 
Regarding the nanoparticles purified by filtration, their weight was not controlled and, 
therefore, it was not possible to formulate the ratio. For this reason, particles purified by 
filtration did not have any cryoprotectant that could stabilize them. Furthermore, during the 
purification phase, the particles purified by filtration, contrary to what occurred with the 
particles purified by centrifugation, were not resuspended in a solution of 0.125% (wt/vol) of 
PVA. As previously referred, PVA is resistant to its complete removal [141], forming a layer at 
the particles’ surface. This layer becomes advantageous at the time of resuspending the 
particles in water, after Freeze-Drying: it leads to the formation of fewer aggregates and, 
therefore, to a more effective stabilization of the particles’ size. Therefore, due to the 
absence of a cryoprotectant and PVA during Freeze-Drying, there was an aggregation 
phenomenon on the particles purified by filtration, leading to the significantly different results: 
for particles prepared with DCM and purified by filtration, the results showed a size of 128.8 ± 
1.2 nm before Freeze-Drying and 591.3 ± 165.0 nm after it; for particles prepared with ACN and 
also purified by filtration, the measured sizes corresponded to 134.2 ± 1.6 nm before Freeze-
Drying and to 361.0 ± 44.5 nm after it.  
When a comparison is performed between the two methods of purification, significant 
differences can also be found. Before Freeze-Drying, particles prepared with DMF and purified 
by centrifugation presented a size of 187.4 ± 4.7 nm, while the ones prepared with the same 
solvent but purified by filtration showed a size of 128.8 ± 1.2 nm; the particles prepared with 
ACN and purified by centrifugation revealed a size of 180.9 ± 3.5 nm, while the ones prepared 
with the same solvent but purified by filtration had a size of 134.2 ± 1.6 nm. This may be 
associated with the presence of particles aggregates: although PVA is present in solution, giving 
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stabilization to the particles, the centrifugation procedure may lead to an incomplete removal 
of aggregates and coalesced particles. Contrarily to what happens in the filtration procedure, 
centrifugation does not warranty the elimination of all particles with a diameter above a well-
defined size, as the aggregates will sediment with the particles [91]. This will lead to the 
presence of larger particles in suspension when compared to the filtration purification 
procedure. However, when comparisons are performed after Freeze-Drying, an opposite 
situation occurs: particles prepared with DMF and purified by centrifugation presented a size of 
182.5 ± 15.3 nm, while the ones prepared with the same solvent but purified by filtration had a 
size of 591.3 ± 165.0 nm; regarding the particles prepared with ACN purified by centrifugation, 
these showed a size of 176.8 ± 1.0 nm, while the ones purified by filtration revealed a size of 
361.0 ± 44.5 nm. These larger sizes associated with particles purified by filtration is related to 
the Freeze-Drying procedure that induced changes in the particles, as above described. 
Therefore, taking into consideration all the results showed, the solvent ACN and 
purification by centrifugation, were the selected parameters for the preparation of particles of 
smaller sizes. Although there were not significant differences between particles prepared with 
ACN and DMF and purified by centrifugation, the reason behind the selection of ACN in 
detriment of DMF relies on the PDI. PDI presents higher values on the samples prepared by DMF, 
when compared to the ones prepared by ACN. As the lower the PDI value, the narrower the 
distribution of sizes, ACN samples were considered more suitable for the pretended application, 
presenting a mean size of 180.9 ± 3.5 nm and 176.8 ± 1.0 nm before and after Freeze-Drying, 
respectively, which is within the predefined initial range for the Small particles (range from 100 
to 200 nm). 
Once all the pretended sizes were obtained after optimization, it was possible to test the 
particles cytotoxicity and their internalization in mice BMC. Table VIII shows the obtained sizes 
for each group of particles used in the following experiments. 
 
Table VIII. Sizes and respective PDI results for the particles used in the cytotoxic assessment and 
internalization studies after 3 and 7 days of cell culture differentiation. These particles were prepared 
accordingly to the previous optimized parameters. Results are presented as Average ± Standard Deviation 
(n=3, i.e., for each condition it was prepared one batch and for each batch 3 measurements were 
performed).  
 
Small Particles 
 
Medium Particles  
 
Large Particles  
 
Size (nm) 
 
PDI 
 
Size (nm) 
 
PDI 
 
Size (nm) 
 
PDI 
3 
Days 
 
188.0 ±  
4.8 
0.112 ± 
0.059 
430.0 ± 
10.1 
0.160 ± 
0.012 
802.6 ± 
48.7 
0.285 ± 
0.012 
7 
Days 
 
195.2 ±  
0.0 
 
0.078 ± 
0.015 
 
417.4±  
11.0 
 
0.162 ± 
0.069 
 
954.6 ± 
31.7 
 
0.220 ± 
0.032 
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4.2. Particles Cytotoxicity 
Cell viability was evaluated by Live/Dead assay, where cells marked with the Calcein AM (a 
green fluorescent dye for viable cells) were considered as being alive and the ones marked with 
Propidium Iodide (a red fluorescent dye for dead cells) were considered as being dead. In order 
to have representative results for each condition, three different areas in each well were 
considered for the counting. Regarding cell metabolic activity, a Resazurin assay was 
performed. Here, considering the control constituted only by BMC as having 100% of metabolic 
activity, the percentages of metabolic activity for the other conditions were calculated. Results 
for cells after 3 and 7 days of culture are represented in Figure 7 and 8, in which A corresponds 
to the Live/Dead results and B to the Resazurin ones. 
No differences were found in cell viability. In what concerns cell metabolic activity, no 
differences were also found between the samples and the control containing only BMC. 
However, to consider a material as being non-cytotoxic, the restrictions imposed by ISO 10993-
5 [152] consider that the metabolic activity of the cells must be maintained above 70%. This 
percentage was not reached by all the conditions, as the average metabolic activity was below 
70% for Coumarin-6 cultured alone with cells, in both days, and for the Small Particles cultured 
with cells after 3 days of culture. Coumarin-6 has been used at higher concentrations without 
showing toxicological results [153]. However, this compound hardly dissolved on the cell culture 
medium at the time of incubation, and, although its concentration was low (0.0006% wt/vol), 
there was a presence of small Coumarin-6 aggregates. As reported by Yu Pan et al. [154], 
nanoparticles are of similar size to typical cellular components and proteins, having the 
capability of bypassing natural mechanical barriers and, consequently, lead to adverse tissue 
reactions. Moreover, when particles are too small, they are endocytosed, instead of phagocyted 
[155, 156], which may result on the binding of particles to intracellular targets, causing 
disturbance on cellular signaling, motility and metabolism [154]. For this reason, and 
considering the aggregates of Coumarin-6 as also being small particles, both Coumarin-6 and 
Small Particles may have been taken by cells through endocytosis, inducing changes in 
metabolic activity and, therefore, revealing lower percentages as presented. However, if 
standard deviations are considered, all showed results present values above 70%, meaning that 
further studies must be performed in this topic in order to confirm the presented results. 
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Figure 7. Particles Cytotoxicity results for BMC after 3 days of differentiation and upon 3 hours of 
incubation with Coumarin-6 loaded particles. These results were assessed by (A) Live/Dead assay and (B) 
Resazurin assay. In the Live Dead assay (A), results were assessed by analyzing three different areas in 
each condition. Viable cells were stained with Calcein AM, presenting a green colour, and dead cells were 
colored as red by Propidium Iodide. Regarding the Resazurin Assay (B), the percentage of metabolic 
activity for each condition was calculated considering cells alone as having 100% of metabolic activity. 
Results are presented as Average ± Standard Deviation (n=1 for A and n=2, i.e., using the same cells, 2 
replicas could be evaluated, for B). Statistical analysis was performed for the results from the Resazurin 
assay, but no differences were found between the conditions and the control containing only cells. Due to 
n being only equal to 1, no statistical analysis was performed for the Live/Dead assay. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Particles Cytotoxicity results for BMC after 7 days of differentiation and upon 3 hours of 
incubation with Coumarin-6 loaded particles. These results were assessed by (A) Live/Dead assay and (B) 
Resazurin assay. In the Live Dead assay (A), results were assessed by analyzing three different areas in 
each condition. Viable cells were stained with Calcein AM, presenting a green color, and dead cells were 
colored as red by Propidium Iodide. Regarding the Resazurin Assay (B), the percentage of metabolic 
activity for each condition was calculated considering cells alone as having 100% of metabolic activity. 
Results are presented as Average ± Standard Deviation (n=1 for A and n=2, i.e., using the same cells, 2 
replicas could be evaluated, for B). Statistical analysis was performed for the results from the Resazurin 
assay, but no differences were found between the conditions and the control containing only cells. Due to 
n being only equal to 1, no statistical analysis was performed for the Live/Dead assay 
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4.3. Evaluation of the Internalization 
BIBP3226 has been studied on our team has a potent antagonist for Y1 receptor. Recently a 
member of our team, Francisco Conceição, has performed works in vitro using BIBP3226 
administrated alone in monocultures and co-cultures of osteoblasts with osteoclasts. However, 
by the time of this project planning, only osteoclasts had revealed conclusive results, showing a 
lower capacity of resorption in the presence of BIBP3226. As in a future work it is aimed to load 
the PLGA particles with BIBP3226 and assess the efficiency of the drug delivery system, it was 
decided that the internalization studies should be performed in osteoclasts, as the readout for 
BIBP3226 effect in these cells was already knew. Therefore, the protocol used here to prepare 
the cell culture was the one used by Francisco Conceição, who has confirmed the presence of 
osteoclasts by performing Tartrate-resistant acid phosphatase (TRAP) staining, TRAP release 
quantification and Real Time Polymerase Chain Reaction (RT-PCR) for genes that typify the 
osteoclast lineage (cathepsin K, osteoclast-associated receptor and calcitonin receptor). 
However, as in this project it was not used any marker to verify the presence of osteoclasts, 
cells with a number of nuclei between 2 to 13 will be referred as multinucleated cells. For the 
same reason, cells with only one nucleus will be referred as mononucleated cells. 
In a first attempt, it was projected that the internalization studies should be assessed by 
Fluorescence Activated Cell Sorting (FACS). However, due to the low quantity of cells, this 
procedure could not be performed. Therefore, analysis by Image Flow Cytometry was executed 
(data not shown); however Coumarin-6 presents a high fluorescence that did not allow the 
distinction between particles and background. Therefore, these two techniques were discarded 
and internalization was assessed by Image Analysis, using images taken in an Inverted 
Fluorescence Microscope. In order to both evaluate cell morphology and particles 
internalization, F-actin filaments were stained in red and the cellular nuclei were marked in 
blue. Results were assessed after 3 hours of incubation with the previously prepared Coumarin-
6 loaded particles, with the sizes referred in Table VIII.  
Regarding the quantity of multinucleated cells, it is observed that after 3 days of culture 
(Figure 9) the amount of multinucleated cells was lower than after 7 days of culture (Figure 
10). If it is assumed that, although markers were not used, the majority of the multinucleated 
cells correspond to osteoclasts, then the results are in agreement with literature, as usually the 
majority of the osteoclastogenesis occurs after 7-8 days of culture [157].  
In order to evaluate the particles’ internalization, firstly the percentage of internalization 
was calculated. In order to calculate this parameter, 6 images (like the representative ones in 
Figure 9 and Figure 10, for the time points of 3 and 7 days, respectively) from different areas 
were analyzed in each condition. By evaluating the cells that had internalized particles, a 
percentage could be calculated (Table IX and X that allowed to construct the graphs in Figure 
11- A and Figure 11-B, for the time points of 3 and 7 days, respectively). The results show that 
less than 50.0% of cells had internalized particles. In what concerns the capacity of 
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internalization, it was observed that mononucleated cells have increased their capacity of 
internalization from the time point of 3 days to the time point of 7 days. In what concerns the 
multinucleated cells, the capacity of uptaking the large particles has decreased with the 
increase of days of culture. The contrary situation happened with the medium particles, as the 
multinucleated cells increased the capacity of internalizing these sized particles from the time 
point of 3 to the one of 7 days.  
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Figure 9. Representative fluorescent micrographs showing Bone Marrow derived Osteoclast Lineage 
Cells (BMC) after 3 days of culture and upon 3 hours of incubation with Coumarin-6 loaded particles. 
Images show fixed and permeabilized BMC either cultured alone (A and B), with 0.000600% (wt/vol) 
Coumarin-6 (C and D) and with 0.0400% (wt/vol) of Small (E and F), Medium (G and H) and Large (I and J) 
particles. Particles had an average size of 188 nm (Small Particles), 430 nm (Medium Particles) and 802 nm 
(Large Particles). F-actin filaments are stained in red, cells’ nuclei are stained in blue and both Coumarin-
6 and particles are represented in color green. Scale bar: 100 µm. 
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Figure 10. Representative fluorescent micrographs showing Bone Marrow derived Osteoclast Lineage 
Cells (BMC) after 7 days of culture and upon 3 hours of incubation with Coumarin-6 loaded particles. 
Images show fixed and permeabilized BMC either cultured alone (A and B), with 0.000600% (wt/vol) 
Coumarin-6 (C and D) and with 0.0400% (wt/vol) of Small (E and F), Medium (G and H) and Large (I and J) 
particles. Particles had an average size of 195 nm (Small Particles), 417 nm (Medium Particles) and 955 nm 
(Large Particles). F-actin filaments are stained in red, cells’ nuclei are stained in blue and both Coumarin-
6 and particles are represented in color green. Scale bar: 100 µm. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Percentage of Internalization of Coumarin-6 loaded particles, upon 3 hours of incubation, 
in mono and multinucleated cells cultured for 3 days (A) and 7 days (B). Illustrative results from Table 
IX and Table X, respectively. The correspondent values of the bars are represented at the top of them. 
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Table IX. Percentage of Internalization of Coumarin-6 loaded particles, upon 3 hours of incubation, in 
mono and multinucleated cells cultured for 3 days. Results were obtained by assessing 6 different spots 
in the well per condition (as described earlier in Figure 9). It was considered that cells had internalized 
particles in all instances where particles were co-localized with the F-actin filaments. Cells and cells with 
Coumarin-6 served as controls to evaluate the effect of Coumarin-6 and the particles in cells. 
 
Table X. Percentage of Internalization of Coumarin-6 loaded particles, upon 3 hours of incubation, in 
mono and multinucleated cells cultured for 7 days. Results were obtained by assessing 6 different spots 
in the well per condition (as described earlier in Figure 11). It was considered that cells had internalized 
particles in all instances where particles were co-localized with the F-actin filaments. Cells and cells with 
Coumarin-6 served as controls to evaluate the effect of Coumarin-6 and the particles in cells. 
 
 
As Small particles were difficult to be visualized, 10 images (like the representative ones 
present in Figure 12 and Figure 13, which represent the cell culture after 3 and 7 days 
respectively) per condition, and from different areas of each well, were observed and analyzed 
at higher magnifications. By assessing these images and by only analyzing the cells that had 
internalized, the number of particles per cell was calculated (Table XI and XII, which allowed to 
construct Figure 14-A and Figure 14-B for the time points of 3 and 7 days respectively). The 
results show that for mononucleated cells the number of particles per cell was maintained, 
with exception for the Large particles. In what concerns the multinucleated cells, there was a 
 
 
 
Total of Cells 
Containing 
Particles 
Total of Cells 
Without 
Particles 
Percentage of 
Internalization 
(%) 
Small  
Particles 
Mononucleated 
 
0 182 0 
Multinucleated 
 
0 9 0 
Medium 
Particles 
Mononucleated 
 
36 142 20.2 
Multinucleated 
 
1 15 6.25 
Large  
Particles 
Mononucleated 
 
44 133 24.9 
Multinucleated 
 
5 11 31.3 
 
 
 
Total Number of 
Cells Containing 
Particles 
Total Number of 
Cells Without 
Particles 
Percentage of 
Internalization 
(%) 
Small 
Particles 
Mononucleated 
 
3 225 1.32 
Multinucleated 
 
0 51 0 
Medium 
Particles 
Mononucleated 
 
81 134 37.7 
Multinucleated 
 
9 29 23.7 
Large 
Particles 
Mononucleated 
 
115 256 31.0 
Multinucleated 
 
14 46 23.3 
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decrease in the number of particles per cell from one time point to another, excluding the 
Small particles, for which there was an increase in the average number per cell. 
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Figure 12. Representative fluorescent micrographs showing Bone Marrow derived Osteoclast Lineage 
Cells (BMC) after 3 days of culture and upon 3 hours of incubation with Coumarin-6 loaded particles. 
Images show fixed and permeabilized BMC cultured alone (A and B), with 0.000600% (wt/vol) Coumarin-6 
(C and D) and with 0.0400% (wt/vol) of Small (E and F), Medium (G and H) and Large (I and J) particles. 
Particles had an average size of 188 nm (Small Particles), 430 nm (Medium Particles) and 802 nm (Large 
Particles). F-actin filaments are stained as red, cells’ nuclei are stained in blue and both Coumarin-6 and 
particles are represented in the color green. Scale bar: 20 µm. 
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Figure 13. Representative fluorescent micrographs showing Bone Marrow derived Osteoclast Lineage 
Cells (BMC) after 7 days of culture and upon 3 hours of incubation with Coumarin-6 loaded particles. 
Images show fixed and permeabilized BMC either cultured alone (A and B), with 0.000600% (wt/vol) 
Coumarin-6 (C and D) and with 0.0400% (wt/vol) of Small (E and F), Medium (G and H) and Large (I and J) 
particles. Particles had an average size of 195 nm (Small Particles), 417 nm (Medium Particles) and 955 nm 
(Large Particles). F-actin filaments are stained in red, cells’ nuclei are stained in blue and both Coumarin-
6 and particles are represented in the color green. Scale bar: 20 µm. 
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Figure 14. Average number of internalized Coumarin-6 loaded particles, upon 3 hours of incubation, 
per mono and multinucleated cell after 3 days (A) and 7 days (B) of incubation. Illustrative results from 
Table XI and XII, respectively. The correspondent values of the bars are represented at the top of them. 
 
Table XI. Average number of internalized Coumarin-6 loaded particles, upon 3 hours of incubation, 
per mono and multinucleated cell after 3 days of culture. Results were obtained by assessing 10 
different spots in the well per condition (as described earlier in Figure 13). It was considered that cells 
had internalized particles in all instances were particles were co-localized with the F-actin filaments. 
Cells and cells with Coumarin-6 served as controls to evaluate the effect of Coumarin-6 and the particles 
in cells. 
 
 
 Total of Cells 
Containing Particles 
 
Total of Counted 
Particles 
 
Average of 
Particles/Cell 
 
Small 
Particles 
Mononucleated 
 
7 40 6 
Multinucleated 
 
0 0 0 
Medium 
Particles 
Mononucleated 
 
11 63 6 
Multinucleated 
 
1 4 4 
Large 
Particles 
Mononucleated 
 
10 100 10 
Multinucleated 
 
1 12 12 
6 6 6 6 
3 
2 
6 6 
10 
10 
4 
 B
 A
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Table XII. Average number of internalized Coumarin-6 loaded particles, upon 3 hours of incubation, 
per mono and multinucleated cell after 7 days of culture. Results were obtained by assessing 10 
different spots in the well per condition (as described earlier in Figure 13). It was considered that cells 
had internalized particles in all instances were particles were co-localized with the F-actin filaments. 
Cells and cells with Coumarin-6 served as controls to evaluate the effect of Coumarin-6 and the particles 
in cells. 
 
Osteoclasts are considered as being part of the mononuclear phagocyte system (MPS) [158]. 
These cells are formed by fusion of circulating mononuclear precursor cells of hematopoietic 
origin, having precursors in common with monocytes and macrophages, which also belong to 
the MPS [158]. As reviewed on literature, although for non-phagocytic cells it is clear that the 
larger the particles, the lower the internalization, for phagocytic cells there is no clear 
evidence that internalization is unequivocally related to the particles size [106]. Moreover, it is 
hypothesized that an optimum particle size to avoid internalization relies between 200 and 500 
nm [108], as particles below 200 nm are internalized  by receptor mediated endocytosis and 
the ones higher than 500 nm are phagocyted [155, 156]. However, the results do not show 
these conclusions, as for the Small particles the internalization was lower. This may be 
associated to the increased difficulty in observing the Small particles. In order to overcome this 
problem, a fluorescent polymer (PLGA marked with fluorescein from Polyscitech) was also 
tested. Accordingly to the supplier, this fluorescent polymer must be mixed with non-
fluorescent PLGA, in a minimum ratio of 1:10. Therefore, this mixture was performed in a ratio 
of 1:4. The particles were then prepared by Nanoprecipitation, accordingly to the previous 
described method. However, results (data not shown) did not show the presence of any 
fluorescent particle. Therefore, as the polymer was not working, it could not be further 
explored for this purpose.  
In what concerns the Large particles, these were, in a general way, internalized at higher 
percentages. However, it was observed that in multinucleated cells, cells with 2 or 3 nuclei 
internalized at a larger scale than cells with more than 8 nuclei. This led to the conclusion that 
as the cell is more mature towards osteoclasts phenotype, it has less capacity to internalize the 
particles. Further studies must be performed on this topic in order to understand this behavior. 
 Total of Cells 
Containing Particles 
 
Total of Counted 
Particles 
 
Average of 
Particles/Cell 
 
Small 
Particles 
Mononucleated 
 
3 17 6 
Multinucleated 
 
4 13 3 
Medium 
Particles 
Mononucleated 
 
21 118 6 
Multinucleated 
 
4 8 2 
Large 
Particles 
Mononucleated 
 
28 154 6 
Multinucleated 
 
11 67 6 
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4.4. Nanofibers 
Considering the fact that the drug delivery system is aimed to be applied locally in a bone 
defect, in addition to the controlled delivery of the drug a support for the particle system must 
also be considered. In a way to circumvent such aspect, in this work it was also considered the 
preparation of nanofibers. Nanofibers can act as a scaffold, providing support for bone 
remodeling. Moreover, they act in the extracellular environment, therefore eliminating the 
disadvantageous variable of internalization, and their high surface area allows higher drug 
loadings [126, 159]. 
In order to test which was the best formulation to obtain nanofibers, different polymer 
concentrations and solvents were experimented (Figure 15). Figure 15-A represents nanofibers 
of 17.0% (wt/vol) PCL in acetone, a formulation optimized and used by another element of 
INEB, Juliana Dias, who kindly offered her solution in order to better understand which were 
the appearance of nanofibers and the behavior of the jet during the electrospinning process. 
Her result shows a randomly organized fiber mat, which arises from a stationary collector.  
However, Figure 15-A only serves as a term of comparison (or a positive control) to the other 
nanofibers’ formulations. Figure 15-B and 17-C correspond to 10% and 13% (wt/vol) of PCL in 
1:0 of DCM:DMF, respectively. As it is observed, instead of obtaining fibers, it was only 
obtained beads. This may be associated to a jet instability referred as droplet-break up, that 
usually occurs in more diluted solutions. This type of instability, instead of electrospinning, 
usually leads to electrospraying, which is described as the process in which electrostatic forces 
are used to form droplets, instead of fibers [122].  In some situations, this instability cannot be 
completely suppressed, leading to beads-on-string morphologies in electrospun fibers, which is 
the morphology present in the fibers of Figure 15-D, that corresponds to 15.0% (wt/vol) of PCL 
in 1:0 of DCM:DMF. However, when the formulations of 10.0%, 13.0% and 15.0% (wt/vol) of PCL 
in 1:0 of DCM:DMF are compared between each other, it can be observed that as the polymer 
concentration is higher, the presence of beads is lower and the result passes from beads to 
fibers with beads. In fact, polymer concentration is of major importance, as it determines the 
spinnability of a solution by influencing both the viscosity and surface tension of the solution 
[120, 126]. If the solution is too diluted, fibers will tend to break and form droplets before 
reaching the collector; on the other hand, if it is too concentrated, then the viscosity will be so 
high that it becomes impossible to form fibers [126]. Therefore, it must be reached a balance 
between too high and too low concentrations, in order to obtain a solution neither too viscous 
nor too diluted. The results show that the percentages of 10.0% and 13.0% (wt/vol) of PCL are 
too low to obtain any kind of fibers, while 15.0% is almost ideal, as it is observed the presence 
of fibers, although with beads. An experiment with higher concentrations probably would result 
in fibers without beads. However, the solution of 15.0% (wt/vol) of PCL was already too 
viscous, leading to some solidification of the fibers in the needle. Therefore, other parameters 
were modified in order to observe the influence of other factors that could result in nanofibers. 
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In what concerns Figure 15-E and F, these correspond to results from the same sample with 
10.0% (wt/vol) of PCL in 4:1 of DCM:DMF. In Figure 15-E it is observed the presence of clusters 
of beads, which may be associated to the deposition of beads with electrically charged solvent, 
that will attract another beads and so on. However, in Figure 15-F the results show the 
presence of fibers with some beads. The difference present in distinct regions of the same 
sample may be associated to some kind of instability during the procedure. As humidity, 
temperature, air density and air viscosity may influence the electrospinning procedure [123], 
some variability on these parameters in a certain period of the procedure may have caused this 
difference on the samples. The addition of DMF intended to augment the viscosity of the 
solution, as well as its conductivity [126, 139]. Conductivity will essentially affect the 
nanofibers’ diameter, which decreases with the solution’s conductivity augmentation [126] and 
viscosity will affect the parameters as previously described. When comparing Figure 15-B and F, 
which in their formulations only differ in the solvent type, it is observed that Figure 15-F has an 
aspect more similar to fibers than Figure 15-B. This may be associated to the solution’s 
viscosity, which was increased with the addition of the DMF solvent.  
Therefore, by analyzing all the parameters, it was conclude that by augmenting the 
polymer’s concentration and the content in DMF, the possibility of obtaining fibers is higher. 
However, the experiments could not be followed due to the degradation of the polymer, which 
may have also been the reason why any of the formulations resulted in the formation of 
nanofibers.  
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Figure 15. Nanofibers produced by electrospinning at 1Kv/cm, with a distance of 14 cm between the 
spinneret and the collector. (A) Results from the solution of 17.0% (wt/vol) of PCL in acetone. (B) Results 
from the solution of 10.0% (wt/vol) of PCL in 1:0 of DCM:DMF. (C) Results from the solution of 13.0% 
(wt/vol) of PCL in 1:0 of DCM:DMF. (D) Results from the solution of 15.0% (wt/vol) of PCL in 1:0 of 
DCM:DMF. (E) and (F) Results from the solution of 10.0% (wt/vol) of PCL in 4:1 of DCM:DMF. All images 
were taken in an Inverted Fluorescence Microscope. Scale bar present in Figure (F). 
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CHAPTER 5 
 
Conclusion and Future Perspectives 
 
 
 
In the present study, it was aimed the formulation and optimization of particles and 
nanofibers-based drug delivery systems for the local delivery of an Y1 receptor antagonist, 
BIBP3226. Two main considerations needed to be taken into account: as BIBP3226 is an 
hydrophobic drug, hydrophobic polymers should be used to prepare the delivery systems and, as 
Y1 receptor is transmembranar, the drug release must occur in the extracellular space.  
Therefore, during these 6 months, PLGA and PCL particles were successfully produced. Due 
to PCL degradation, PLGA was chosen to procced with the project. Two methods (Salting-out 
and Nanoprecipitation) were optimized for the attainment of PLGA particles with sizes 
comprised between 100 nm and 200 nm, 400 nm and 500 nm, 800 nm and 1000 nm. After 
obtaining particles with sizes within these ranges, their cytotoxicity was studied and 
internalization rates were assessed in Bone Marrow derived cells. Any of the differently sized 
particles has shown cytotoxicity, as cells remained viable and with high levels of metabolic 
activity. In what concerns their internalization, results have shown higher rates of 
internalization for the particles within the range from 800 nm to 1000 nm, when compared to 
particles with sizes from 400 nm to 500 nm. In what concerns particles with sizes from 100 nm 
to 200 nm, results were inconclusive. Besides these studies, it was also assessed if a variation 
on the volumes used in the preparation of particles by the Salting-out method would influence 
the particles size and drug loading efficiency. Results have shown that size is not influenced, 
but in what concerns drug loading efficiency, it may have influence. However, further 
experiments should be performed in order to confirm the results. In what concerns nanofibers, 
as the polymer was degraded, conclusions could not be taken for the tested formulations. 
During my Master thesis, I was able to attain experience in particles preparation by two 
different methods, nanofibers preparation by electrospinning, cell culture techniques, Confocal 
and Inverted Fluorescence Microscopy and Image Flow Cytometry. However, due to time 
restrictions and difficulties with equipment and materials, some limitations were imposed. 
Namely the number of replicas in some experiments was too low, the evaluation of results 
could not be performed as initially expected and experiments could not be carried on. 
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Therefore, some future improvements are here proposed in order to confirm the obtained 
conclusions.  
Filtration was performed as a purification method in the Nanoprecipitation method, 
revealing good results for particles’ size before Freeze-Drying. This purification procedure must 
be studied in what concerns mass losses and possibilities of introducing some kind of 
cryoprotectant or surfactant, in order to raise the particles stability during Freeze-Drying. By 
performing this study, if filtration shows good results for the aforementioned parameters, 
centrifugation can be substituted by this procedure, as filtration is more efficient in the 
elimination of aggregates and coalesced particles. 
In what concerns the internalization studies, these must be performed using a polymer 
marked with fluorescence, as it not only eliminates the release kinetics present in Coumarin-6 
loaded particles, but also allows the evaluation of results by Image Flow Cytometry. Besides 
this method, results should be assessed by FACS or by measuring the total fluorescence of the 
image, which was not possible due to the high fluorescence of Coumarin-6. Regarding the cells, 
it must be assessed if the cells present in culture are osteoclasts, by using the same markers 
that Francisco Conceição has used (TRAP staining, TRAP release quantification RT-PCR for genes 
that typify the osteoclast lineage, like cathepsin K, osteoclast-associated receptor and 
calcitonin receptor).  
As nanofibers could not be produced due to the polymer degradation, the procedure should 
be repeated with new PCL in order to evaluate the tested conditions and obtain nanofibers. 
As general future improvements, more replicas should be performed in every experiment in 
order to confirm the obtained results. Consequently, the optimized particles and nanofibers 
should be tested in what concerns their release kinetics and loading capacities. By optimizing 
these two parameters, the two delivery systems should be tested in the delivery of BIBP3226 at 
bone marrow derived cells and, after assessing these results, studies should be performed in 
vivo. 
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